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Abstract
Das B-lymphotropische Epstein-Barr Virus findet sich bei über 90% der humanen Weltbevölkerung.
Nach Primärinfektion etabliert EBV eine lebenslang ausdauernde latente Infektion innerhalb der
Gedächtnis B-Zellen des Wirtes. Eventuell kann diese latente Infektion zu mit EBV assoziierten
Tumoren wie dem endemischen Burkitt's Lymphom, der Hodgkin Krankheit oder Lymphomen nach
Organtransplantationen führen. Ein wichtiger Kofaktor, für die onkogene Transformation der
EBV-infizierten B-Zellen ist eine chronische Aktivierung des Immunsystems, wie bei einer HIV- oder
Malariainfektion zu beobachtet ist. Modelle für die Etablierung der latenten Infektion von EBV gehen
davon aus, dass EBV in den Tonsillen entweder naïve oder Keimzell-B-Zellen infiziert. Über virale
Proteine kommt es dann zu einer Antigen-unabhängigen Reifung zu Gedächtnis B-Zellen. Nach der
Rückkehr dieser EBV-infizierten Gedächtnis-B-Zellen und Kontakt mit fremdem Antigen, wird EBV
während der endgültigen Reifung zu Plasmazellen reaktiviert. Da für eine Effiziente Aktivierung von
Gedächtnis-B-Zellen eine Antigen-Selektion unumgänglich ist, muss auch eine direkte Infektion von
Gedächtnis-B-Zellen mit EBV möglich sein. Tatsächlich zeigten in vitro-Untersuchungen, dass
Gedächtnis-B-Zellen aus dem Nasopharynx mit EBV infizierbar sind. Diese sind bereits durch
Antigenkontakt selektiert worden und können somit auch zu Plasmazellen reifen. Die Infektion von
Gedächtnis-B-Zellen wird vor allem durch zwei Faktoren gewährleistet. β1 Integrine welche spezifisch
auf Gedächtnis-B-Zellen exprimiert werden, die in den Tonsillen gebildet wurden werden von EBV für
die Bindung an die Zelle benutzt. Hierbei wird ein Signalübertragungsweg ausgelöst, der über eine
erhöhte Depolymerisation des Aktin-Cytoskeletts zu einer erhöhten Aufnahme von EBV in die Zelle
führt. Des Weiteren kommt es in den Keimzentren der Tonsille zu einem Transfer von EBV von
follikulären Dendritischen Zellen auf Gedächtnis-B-Zellen, was ebenfalls zu einer effizienteren
Infektion führt. Eine erhöhte Grundaktivierung des Immunsystems, hauptsächlich über Interleukin 12,
Interferon γ und Interleukin 2 bewirkt eine Inhibierung der Replikation von EBV und somit zu einer
Anhäufung latent mit EBV infizierten B-Zellen. Besonders ausgeprägt ist dieser Effekt bei chronischer
Aktivierung von Toll-like Rezeptor 9 zu beobachten, der auch von Malaria stimuliert wird. Durch die
erhöhte Anzahl latent infizierter Zellen ist auch die Wahrscheinlichkeit erhöht, dass es zu einer
onkogenen Mutation der Zellen kommt.
Summary: The human B-lymphotropic Epstein-Barr virus infects over 90% of the human adult
population. Following primary infection, EBV establishes a latent infection and life-long persistence
within the memory B cell pool. Eventually, latent infection may lead to the formation of several
EBV-associated malignancies such as Burkitt's lymphoma, Hodgkin's disease or post-transplant
lymphoproliferative disease. An important cofactor influencing the oncogenic transformation of
EBV-infected B cells is chronic immune activation as observed in HIV or chronic malaria infection in
areas of sub-Saharan Africa. Models of how EBV establishes persistence in B cells hold that EBV
initially enters the nasopharynx-associated lymphatic tissue including tonsils to infect either a naïve or a
germinal center B cell. Expression of EBV latent proteins is thought to drive antigen-independent
differentiation to memory B cells, which exit the lymphatic tissue to circulate within the body. Upon
homing back to the tonsil and contact with antigen terminal differentiation of the memory B cell to
plasma cells is induced and EBV reactivates from latency. As a functional, antigen-selected B cell
receptor is a prerequisite for efficient activation of memory B cells, we tackeled the question whether
EBV is also able to directly infect memory B cells that successfully underwent affinity maturation by
antigen. Indeed, we show that memory B cells from tonsils are susceptible to EBV infection, thereby
providing an alternative route for EBV to establish persistence within the host. The ability of EBV to
infect memory B cells is regulated via the expression of β1 integrin, a recently identified coreceptor for
EBV specifically expressed on NALT-originating memory B cells and by the follicular dendritic cell
network of the germinal centers, which we could identify as a reservoir for EBV transferring infectious
virus preferentially to memory B cells. Immune activation, as measured by the expression levels of
proinflammatory cytokines interleukin 12, interferon γ or interleukin 2 could be demonstrated to
influence the balance between EBV latent and lytic infection, favoring latent infection of B cells.
Especially Toll-like receptor 9, which is chronically stimulated during malaria infection leads to an
inhibition of EBV replication, thereby leading to an increased number of latently infected cells which
then in turn increase the likelihood of an oncogenic transformation.
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We must not forget that when radium was 
discovered no one knew that it would prove useful in 
hospitals. The work was one of pure science. And this is 
a proof that scientific work must not be considered from 
the point of view of the direct usefulness of it. It must be 
done for itself, for the beauty of science, and then there 
is always the chance that a scientific discovery may 
become like the radium a benefit for humanity. 
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1. Summary 
The human B-lymphotropic Epstein-Barr virus infects over 90% of the human adult 
population. Following primary infection, EBV establishes a latent infection and life-long 
persistence within the memory B cell pool. Eventually, latent infection may lead to the 
formation of several EBV-associated malignancies such as Burkitt’s lymphoma, Hodgkin’s 
disease or post-transplant lymphoproliferative disease. An important cofactor influencing the 
oncogenic transformation of EBV-infected B cells is chronic immune activation as observed 
in HIV or chronic malaria infection in areas of sub-Saharan Africa. 
Models of how EBV establishes persistence in B cells hold that EBV initially enters 
the nasopharynx-associated lymphatic tissue including tonsils to infect either a naïve or a 
germinal center B cell. Expression of EBV latent proteins is thought to drive antigen-
independent differentiation to memory B cells, which exit the lymphatic tissue to circulate 
within the body. Upon homing back to the tonsil and contact with antigen terminal 
differentiation of the memory B cell to plasma cells is induced and EBV reactivates from 
latency. 
As a functional, antigen-selected B cell receptor is a prerequisite for efficient 
activation of memory B cells, we tackeled the question whether EBV is also able to directly 
infect memory B cells that successfully underwent affinity maturation by antigen. Indeed, we 
show that memory B cells from tonsils are susceptible to EBV infection, thereby providing an 
alternative route for EBV to establish persistence within the host. The ability of EBV to infect 
memory B cells is regulated via the expression of β1 integrin, a recently identified coreceptor 
for EBV specifically expressed on NALT-originating memory B cells and by the follicular 
dendritic cell network of the germinal centers, which we could identify as a reservoir for EBV 
transferring infectious virus preferentially to memory B cells. 
Immune activation, as measured by the expression levels of proinflammatory 
cytokines interleukin 12, interferon γ or interleukin 2 could be demonstrated to influence the 
balance between EBV latent and lytic infection, favoring latent infection of B cells. 
Especially Toll-like receptor 9, which is chronically stimulated during malaria infection leads 
to an inhibition of EBV replication, thereby leading to an increased number of latently 
infected cells which then in turn increase the likelihood of an oncogenic transformation. 
 2. Zusammenfassung 
Das B-lymphotropische Epstein-Barr Virus findet sich bei über 90% der humanen  
Weltbevölkerung. Nach Primärinfektion etabliert EBV eine lebenslang ausdauernde latente 
Infektion innerhalb der Gedächtnis B-Zellen des Wirtes. Eventuell kann diese latente 
Infektion zu mit EBV assoziierten Tumoren wie dem endemischen Burkitt’s Lymphom, der 
Hodgkin Krankheit oder Lymphomen nach Organtransplantationen führen. Ein wichtiger 
Kofaktor, für die onkogene Transformation der EBV-infizierten B-Zellen ist eine chronische 
Aktivierung des Immunsystems, wie bei einer HIV- oder Malariainfektion zu beobachtet ist.  
Modelle für die Etablierung der latenten Infektion von EBV gehen davon aus, dass 
EBV in den Tonsillen entweder naïve oder Keimzell-B-Zellen infiziert. Über virale Proteine 
kommt es dann zu einer Antigen-unabhängigen Reifung zu Gedächtnis B-Zellen. Nach der 
Rückkehr dieser EBV-infizierten Gedächtnis-B-Zellen und Kontakt mit fremdem Antigen, 
wird EBV während der endgültigen Reifung zu Plasmazellen reaktiviert.  
Da für eine Effiziente Aktivierung von Gedächtnis-B-Zellen eine Antigen-Selektion 
unumgänglich ist, muss auch eine direkte Infektion von Gedächtnis-B-Zellen mit EBV 
möglich sein. Tatsächlich zeigten in vitro-Untersuchungen, dass Gedächtnis-B-Zellen aus 
dem Nasopharynx mit EBV infizierbar sind. Diese sind bereits durch Antigenkontakt 
selektiert worden und können somit auch zu Plasmazellen reifen. Die Infektion von 
Gedächtnis-B-Zellen wird vor allem durch zwei Faktoren gewährleistet. β1 Integrine welche 
spezifisch auf Gedächtnis-B-Zellen exprimiert werden, die in den Tonsillen gebildet wurden 
werden von EBV für die Bindung an die Zelle benutzt. Hierbei wird ein 
Signalübertragungsweg ausgelöst, der über eine erhöhte Depolymerisation des Aktin-
Cytoskeletts zu einer erhöhten Aufnahme von EBV in die Zelle führt. Des Weiteren kommt es 
in den Keimzentren der Tonsille zu einem Transfer von EBV von follikulären Dendritischen 
Zellen auf Gedächtnis-B-Zellen, was ebenfalls zu einer effizienteren Infektion führt. 
Eine erhöhte Grundaktivierung des Immunsystems, hauptsächlich über Interleukin 12, 
Interferon γ und Interleukin 2 bewirkt eine Inhibierung der Replikation von EBV und somit zu 
einer Anhäufung latent mit EBV infizierten B-Zellen. Besonders ausgeprägt ist dieser Effekt 
bei chronischer Aktivierung von Toll-like Rezeptor 9 zu beobachten, der auch von Malaria 
stimuliert wird. Durch die erhöhte Anzahl latent infizierter Zellen ist auch die 
Wahrscheinlichkeit erhöht, dass es zu einer onkogenen Mutation der Zellen kommt.
 2
Introduction 
3. Introduction 
3.1. Epstein-Barr virus 
The Epstein-Barr virus (EBV), a herpesvirus of the γ-L or lymphocryptovirus (LCV) 
genus was discovered through the observations of Denis Burkitt and Anthony Epstein of 
multifocal jaw tumors in children in Kampala in 19641. The tumors were lymphomas 
prevalent in children in climates supportive of holoendemic malaria2-4. After successful 
culturing of the lymphoma cells, they could identify a herpesvirus in electron micrographs1. 
The Burkitt's lymphoma (BL) tumor virus differed from known human herpesviruses as it was 
noninfectious for cultured cell lines and nonreactive with antibodies to other human 
herpesviruses. Besides the Kaposi’s sarcoma-associated herpesvirus (KSHV), EBV is the only 
known human γ-herpesvirus. 
EBV displays the two classical characteristics of the γ-herpesvirus family (Table 1). 
Firstly, it is widespread in all human populations, with more than 90% of adults positive for 
serum IgG antibodies. Second, the virus persists for life in the immune host and, can be 
rescued in vitro from circulating lymphocytes when using spontaneous B-cell transformation. 
Primary Infection with EBV is usually asymptomatic in infants and toddlers, whereas 
infection of older children, adolescents and adults may manifest with the clinical symptoms of 
infectious mononucleosis, a vigorous immune hyperactivation5. These symptoms include 
fever, enlarged tonsils and lymph nodes, sore throat, muscle weakness, enlarged spleen and 
abdominal pain6. Infectious mononucleosis is generally self-limiting and only symptomatic 
and/or supportive treatments are used. During primary infection, EBV establishes a life-long 
persistence within the B cell pool of the host. 
 
Table 1. Human herpesviridae 
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3.2. EBV-associated malignancies 
EBV is associated with various lymphomas and cancers. These include immunoblastic 
lymphoma of immunosuppressed, Burkitt’s lymphoma (BL), Hodgkin's lymphoma (HL), 
post-transplant lymphoproliferative disease arising in organ transplant patients as well as 
several nasal T/NK lymphoma, lymphoepitheliomas of the nasopharynx, thymus and stomach and 
leiomyosarcomas7,8. 
 
Table 2. EBV-associated malignancies 
 
 
As in persistent infection for different B cell differentiation stages, the array of EBV 
genes that is expressed in EBV-associated malignancies differs9. The more immune 
competent the host, the less genes EBV expresses to evade immune recognition. 
 
Table 3. EBV gene expression in EBV-associated malignancies 
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3.2.1. Burkitt’s lymphoma 
Burkitt lymphoma (BL) is an aggressive B-cell malignancy, which can be classified 
into three forms which differ in geographic distribution, Epstein–Barr virus (EBV) 
association, and immunocompetence status: endemic (eBL), sporadic (sBL) and HIV-
associated BL4,8,10,11. There is a low background incidence of BL worldwide (sBL), which is 
rarely associated with EBV and accounts for 1–2% of adult lymphoma in Western Europe and 
America. In contrast eBL is associated with (EBV) in over 95% of cases and is predominant 
in the equatorial belt of Africa and other parts of the world where malaria is hyperendemic. 
BLs that display an intermediate association with EBV have also been documented in Egypt 
and Brazil, where up to 87% of tumors are EBV positive and BL occurs in HIV carriers, 
where tumors can develop prior to the severe immunosuppression coincident with the onset of 
AIDS. Approximately 30% of such AIDS-associated tumors are EBV-positive. Endemic 
EBV-associated BL has an incidence of 5–10/100 000 children and accounts for up to 74% of 
childhood malignancies in the African equatorial belt. In contrast to sBL, which most 
frequently involves tumors of the abdomen, eBL often presents in the jaw or kidneys but may 
also occur in the abdomen, ovaries, facial bones and other extranodal sites12. The cancer has 
one of the highest cell proliferation rates of any human tumor (doubling time of tumor 24–48 
h).  
A hallmark of BL is the translocation of the proto-oncogene MYC into one of the 
immunoglobulin loci, resulting in constitutive activity of this transcription factor10. This 
misregulated expression of MYC in turn is responsible for the rapid proliferation and tumor 
formation. The structure of the chromosome breakpoints of the MYC translocation strongly 
indicates that the translocations occurred either as a mistake of class-switch recombination or 
somatic hypermutation (SHM)13. Moreover, mutations of the gene encoding the tumor 
suppressor p53 are found in a third of cases of BL, and there is also evidence for genetic 
alterations of the putative tumor suppressor gene retinoblastoma-like 2 (RB2) in most cases of 
eBL and sBL. Additionally, EBV drives proliferation of the cell by initiating the latency III 
growth program before shutting-down its gene expression and establishment of the latent 
infected B cell pool. In BL, key steps of malignant transformation probably occur in an EBV-
infected B cell residing in a germinal center14,15.  
Histologically, BL cells are monomorphic medium sized cells with round nuclei, a 
number of nucleoli and abundant cytoplasm12. Tumors contain high numbers of macrophages, 
which phagocytose apoptotic debris. BL tumor cells usually express IgM, B-cell markers such 
as CD19, CD20 and CD22 and markers of GC centroblasts such as CD10, BCL6 and the 
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human GC-associated lymphoma (HGAL) protein. The cell surface phenotype of BL tumor 
cells reflects a GC origin but the site of tumor growth is frequently the jaw or ovary, neither of 
which normally contains GCs. However, the tumor cells have undergone SHM, a feature of 
the GC reaction during B-cell activation and differentiation. Moreover, the breakpoint in the 
Ig gene to which MYC is transferred in eBL occurs at the V(D)J region, suggesting that 
translocation occurs during V(D)J recombination. The J segments flanking MYC translocated 
breakpoints typically exhibit deletions and/or additions of base pairs characteristic of normal 
Ig V(D)J segment rearrangement. This is a process catalysed by B-cell specific V(D)J 
recombinase activating enzymes RAG-1/2 which are expressed in both pre-B cells and GC B 
cells16. In contrast, the chromosomal breakpoint in sBL and HIV-associated BL occurs most 
commonly in the class switch region, but since both somatic hypermutation and class 
switching are events that are normally confined to GC B cells and GC centroblast markers are 
expressed on BL cells, the BL progenitor cells most likely arise from B cells subjected to 
chromosomal rearrangements in the GC.  
There is some evidence that the cell of origin may be a post-GC or memory B cell re-
entering the GC and may differ in EBV-positive and negative tumors, but whichever is the 
cell of origin, it is clear that GC involvement is critical to the pathogenesis of this disease both 
in terms of MYC translocation events and the contribution of co-factors such as EBV, malaria 
or HIV infection.  
EBNA1 is normally the only EBV-encoded protein expressed by BL cells. Its 
oncogenic potential is debated. EBERs, which are also transcribed, can induce the expression 
of interleukin-10 (IL-10) and mediate resistance to interferon-α (IFN-α), which might support 
tumor growth and survival. 
3.2.2. Hodgkin’s disease 
Hodgkin lymphoma is characterized by atypical, large tumor cells known as Hodgkin 
and Reed–Sternberg (HRS) cells17-20. These cells usually represent less than 1% of cells in the 
tumor tissue. Most cells in the tumor are non-malignant T cells, B cells, eosinophils and 
others. Based on differences in the histology and immunophenotype of HRS cells, a classical 
form of Hodgkin lymphoma, accounting for 95% of cases, is distinguished from a lymphocyte 
predominant form. HRS cells of lymphocyte-predominant Hodgkin lymphoma are always 
EBV negative, whereas in ~40% of cases of classical Hodgkin lymphoma in the Western 
world, EBV is detected in the lymphoma cells. In EBV-positive cases, three EBV proteins are 
expressed, that is EBNA1, LMP1 and LMP2A (latency II). The cellular origin of HRS cells of 
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classical Hodgkin lymphoma has long been unclear, partly because they do not resemble any 
normal haematopoietic cell type. Single-cell molecular analysis showed that HRS cells in 
nearly all cases derive from B cells15. The rearranged immunoglobulin V genes of HRS are 
somatically mutated, but lack intraclonal V gene diversity, indicating that the SHM machinery 
is silenced in the tumor cells. Germinal-centre B cells that acquire such ‘crippling’ mutations 
are normally efficiently eliminated by apoptosis in the germinal centre. The expression 
pattern of EBV-encoded genes in HRS cells indicates a role for EBV in the rescue and 
transformation of pre-apoptotic GC B cells21. Two of the main survival signals for GC B cells 
are mediated through the BCR and through stimulation of CD40. These signals can 
presumably be replaced by LMP2A and LMP1, respectively, both of which are expressed by 
EBV-positive HRS cells. 
HRS cells have lost the expression of most B cell-specific genes crucial for BCR 
signaling. Perhaps, the global loss of the B cell identity that is associated with the generation 
of HRS cells allows these cells to escape the normal selection forces of B-lineage cells to 
express a functional antigen receptor and allows survival of the transformed cells in the 
absence of a BCR. 
3.2.3. Post-transplant lymphoma 
The T-cell immunosuppressive therapy given to patients after transplantation is 
associated with a greatly increased risk of lymphoproliferative diseases. These post-
transplantation lymphoproliferative diseases (PTLDs) are nearly always of B cell origin and 
EBV positive22,23. Most probably, the suppression of T-cell responses allows uncontrolled 
proliferation of EBV-transformed B cells. PTLDs can present as polyclonal expansions, but 
many cases show oligoclonality or monoclonality. In the latter situation, some EBV-
transformed B cells might have acquired additional transforming events, finally leading to the 
outgrowth of a malignant B cell clone from an initially poly- or oligoclonal expansion. The 
EBV-positive B cells in PTLDs often have a latency III profile, but more restricted gene-
expression patterns are also observed. The detection of SHM activity and/or crippling 
mutations in a considerable fraction of monoclonal PTLD clones indicates that these 
lymphomas often derive from germinal-center B cells. 
3.3. Latency programs of EBV at and after primary infection  
Epstein-Barr virus infection of primary B cells, in vitro, results in the cells becoming 
latently infected. 3% to 10% of those cells start proliferating as immortal or transformed 
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lymphoblastoid cell lines (LCL)24. The mechanism of this remarkable effect depends on the 
expression of nine viral latent proteins that are under the control of a master regulatory 
transcription factor, EBV nuclear antigen 2 (EBNA2)25. In vitro events are very different from 
what occurs in the blood of healthy carriers of the virus. Here, up to 1 in 106 B cells are also 
latently infected with EBV. These cells are all memory B cells that are in a resting state and 
they express no viral proteins26. They are recognizable as EBV infected by their expression of 
EBERs (non-coding EBV RNAs). Cells that express the growth program are found only in the 
lymph nodes and possess a naïve phenotype. Depending on the differentiation stage of the 
infected B cell, EBV activates a distinct gene expression program (Table 2)26. The Growth 
program is defined as the EBV expression pattern detected when EBV infects naïve B-cells 
(EBNA1-6 (EBV nuclear antigen), LMP1 (latent membrane protein 1), LMP2A, LMP2B, and 
EBERs (EBV-encoded RNA)). In EBV-infected germinal center (GC) B cells, the Default 
program is predominantly switched on, comprised by the expression of EBNA1, LMP1, LMP2A, 
LMP2B, and EBERs. In resting memory B cells carrying EBV, viral gene expression is tightly 
restricted to the expression of EBERs with EBNA1 and LMP2 only being expressed during cell 
division.  
Besides the different latency programs, EBV also reactivates from latency from time 
to time, initially activated by expression of BZLF1 and followed by transcription of all lytic 
genes, virus assembly and budding. 
 
Table 4. Patterns of EBV gene expression depending on B cell differentiation stage  
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3.4. EBV entry  
Eight virus glycoproteins have been implicated in some way in EBV entry into either a 
B cell or an epithelial cell. EBV requires at least two host cell factors for efficient binding and 
entry into B cells. CD21 is an efficient initial EBV receptor and is also the receptor for the 
C3d component of complement27-31. Purified CD21 binds to EBV and can block B-cell 
infection32-34. The most abundant EBV outer envelope glycoprotein, gp350/220 is binding to 
EBV thereby facilitating virus adsorption to the cell35,36. Furthermore, soluble gp350/220 can 
saturate B-lymphocyte receptors and block virus infection, confirming a key role for 
gp350/220 in virus adsorption37. Binding of gp350/220 also triggers capping of CR2 and 
endocytosis of the virus38. CR2 can function as a signal transducer both independently and as 
part of a signal transduction complex that includes CD19 and CD3539. Cross-linking by 
gp350/220 activates NF-κB40 and induces interleukin-6 via a protein kinase C pathway40. 
None of these signaling events may be critical to penetration of the cell membrane, but they 
clearly have potential consequences for downstream events in infection. 
Fusion of the EBV envelope with both a B cell and an epithelial cell membrane 
requires three glycoproteins, gH/gL and gB, which are conserved throughout the herpesvirus 
family and which have been referred to as the core fusion machinery41,42. Within the three-part 
complex of gHgLgp42 in the virus, this interaction is now thought to provide the trigger for B-
cell fusion. Binding of gp42 to HLA class II shows some allelic specificity in that 
nonfunctional HLA-DQ alleles have been identified43, but since all three alleles, HLA-DP, 
HLA-DQ, and HLA-DR, can be used, it seems unlikely that this has a major impact in an 
outbred human population. 
Recently, we and others have reported that EBV might use another glycoprotein, 
BMRF2 as an attachment factor to epithelial cells and memory B cells from the tonsil44-46. By 
binding to its cellular receptor, the β1 subfamily of integrins, EBV triggers actin 
depolymerization through activation of focal adhesion kinase (FAK), c-Src and PI3 kinases, 
thereby enhancing susceptability of these cells to EBV infection47-49.  
 9
Introduction 
 
Figure 1. Molecular events required for efficient infection of B cells with EBV. After initial binding of EBV 
gp350 to cellular CD21, receptor-mediated endocytosis is triggered. Within the endosomes, a viral glycoprotein 
complex consisting of gH, gL and gp42 binds to HLA class II molecules ultimately leading to membrane fusion 
of EBV with the endosomal membrane. A fifth EBV glycoprotein, BMRF2, may also bind to cellular β1 
integrins, thereby mediating actin depolymerization followed by more efficient EBV entry and nuclear transport. 
3.5. Establishment of Epstein-Barr virus persistence 
3.5.1. B cell maturation 
B cell development occurs in a series of discrete stages beginning within the fetal liver 
as early as eight weeks gestation, and maintenance in bone marrow for the rest of the life50,51. 
The first recognizable developmental stage is the rapidly-dividing pre-B cell which 
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synthesizes cytoplasmic IgM but lacks surface receptors for antigen52,53. Immature B 
lymphocytes emerging from pre-B cells express surface IgM, but are uniquely susceptible to 
inactivation as a consequence of specific antigen binding. After finishing the development to a 
mature B cell, it exits the bone marrow and homes to the secondary lymphoid organs54, where 
all further differentiation steps take place. Dendritic cells, which collect antigen in the 
periphery and at the epithelial barriers, present them to the antigen-naïve B cells and T cells 
and initiate rapid proliferation of the responsive B cell clones which then form the germinal 
center (GC). It is here, where the antigen-driven selection takes place, leading to the 
generation of highly antigen-specific memory B cells. Furthermore, the dendritic cells with 
bound antigen serve to stimulate TH2 differentiation of CD4+ T cells which is an important 
cofactor for the GC reaction. Only if the B cell recognizes the antigen with its BCR, it forms a 
so-called immunological synapse with the DC and the T cell, receiving survival signals 
through the BCR and a CD40-CD40L interaction with the T cell. This in turn activates the 
somatic hypermutation machinery in the B cell which ultimately serves to increase the antigen 
specificity of the BCR by inserting mutations within distinct hotspot regions within the 
immunoglobulin variable region. In the course of the selection process, the T cells secrete a 
defined pattern of cytokines and chemokines which then initiate the last step of antigen-driven 
selection, the isotype switch. This leads to the excision of immunoglobulin constant regions, 
leading to the expression of IgG, IgA, or IgE instead of IgM. The pattern of secreted 
cytokines regulates, which immunoglobulin isotype is produced. Following successful 
completion of the GC reaction, the B cell exits the lymphoid tissue as a memory B cell to 
patrol the periphery for cognate antigen. Engagement of the BCR by an apt antigen then 
initiates the last step in B cell differentiation, terminal differentiation to an antibody-
producing plasma cell synthesizing IgM, IgD, IgG, IgA, or IgE immunoglobulins, 
respectively. 
3.5.2. Establishment of EBV persistence 
In healthy, EBV-seropositive individuals, EBV persistence in the peripheral blood is 
strictly confined to CD27+ IgD- memory B cells and absent from the IgD-, CD27-, naïve B cell 
subset55,56. This has given rise to a model for EBV colonization of the B cell pool in which 
virus infection of a naïve B cell mimics the process of antigen-driven differentiation and 
drives that cell's progeny to acquire memory status57. The generated “phenotypic” memory B 
cells that bypassed affinity maturation then exit the tonsil and enter the peripheral circulation. 
Upon activation of these EBV-harboring cells homing back to the tonsils by so far unknown 
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mechanisms, terminal differentiation to plasma cells is initiated by the unfolded protein 
pathway ultimately leading to X-Box binding protein (XBP)-1 expression58. This in turn 
activates EBV lytic replication and the production of progeny virions. 
Even though this model has been widely accepted, additional findings suggest in 
addition EBV infection occuring at different stages later than naïve B cells.  
3.5.2.1. Primary infection of naïve B cells 
David Thorley-Lawson was the first to postulate a model for EBV persistence based 
on an initial infection of naïve B cells within the tonsil56,57,59-66. This is based on the finding of 
only naïve B cells within the tonsil expressing the growth program required for the 
transformation of B cells in vitro61. The model holds that, upon infection of a naïve B cell, 
EBV activates B cells to become proliferating blasts so that they can then differentiate into 
resting memory B cells simulating the process of the GC reaction67. This process parallels the 
activation of a naive B cell on exposure to an antigen. It is in the GC that an activated naive B 
cell blast that is responding to a foreign antigen during an immune response undergoes the 
transition into a long-lived memory B cell. The antigen-activated B cell is rescued through 
entry into the pool of memory B cells when it receives signals from antigen and antigen-
specific helper T cells. As EBV expresses LMP1 and LMP2 during the default program, 
thereby mimicking CD40-CD40L interaction and an activated B cell receptor (BCR), it 
delivers the rescue signals to the latently infected blast65. Then the memory cells enter the 
peripheral circulation. In response to so far unknown signals, memory B cells may 
differentiate into plasma cells and secrete antibody. If such a cell contains EBV, it will 
reactivate viral replication and infectious virus will be produced58,62. 
 
Figure 2. Model for EBV persistence by initial infection of naïve B cells. EBV, not antigen stimulation and T 
cell help provide the required survival signals necessary for memory B cell differentiation of the EBV-infected 
naïve B cells (adapted from 57). 
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3.5.2.2. Primary infection of germinal center B cells 
Even though EBV-infected B cells are only very rarely detectable in the germinal 
center, it could be shown, that centroblasts and centrocytes are susceptible to EBV 
infection19,68-72. Infected GC B cells express LMP1 and LMP2, providing the cells with 
survival signals even in the absence of a functional BCR or CD40 signaling73-76. This in turn 
drives the GC B cell to differentiate to a memory B cell, even if the B cell carries a “crippled” 
BCR, i.e. a BCR unable to respond to foreign antigen68.  
3.5.2.3. Primary infection of memory B cells 
Together with the finding that EBV is able to infect GC B cells directly, it was first 
suggested by us and others that EBV could also directly infect antigen-selected memory B 
cells71,77. Such infection would minimize the risk for the EBV-infected B cell to undergo 
apoptosis in the GC reaction. Furthermore, it would explain, how EBV-reactivated from 
infected memory B cells to produce new EB virions. As the memory B cells successfully 
underwent affinity maturation, somatic hypermutation (SHM) and class-switch recombination 
(CSR) within the GC prior to EBV infection they will still respond to cognate antigen 
exposure with high specificity78,79. Finally, this model bears another advantage over the 
previous two models as the memory B cells are able to respond to cognate antigen. Depending 
on the binding strength of the BCR-antigen-interaction, the cell will either start to proliferate 
extensively, spreading throughout the host to serve as sentinels for a possible site of pathogen 
invasion, or the BCR signal will activate the memory B cells which is subsequently 
undergoing terminal plasma cell differentiation80. This in turn activates XBP-1, which 
activates EBV lytic replication58,81. Therefore, the EBV life-cycle can be completed upon 
terminal differentiation of the EBV-infected memory B cell simply by antigen encounter. 
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Figure 3. Models for the establishment of EBV persistence. (A) Initial infection of naïve B cells. Naïve B 
cells are provided with survival signals by EBV gene products instead of antigen-affinity. The resulting memory 
B cells carry a non-specific BCR not responding to foreign antigen. (B) Initial infection of GC B cells. EBV 
infects GC B cells currently in the phase of SHM and CSR, resulting in “crippled” BCR-expressing EBV-
infected memory B cells. (C) Infection of affinity-matured antigen-specific memory B cells providing the 
missing explanation how EBV is transmitted due to BCR stimulation and EBV lytic cycle reactivation. 
3.5.2.4. The role of follicular dendritic cells in the establishment of EBV persistence 
Follicular dendritic cells (FDC) are the body’s most potent antigen-presenting cells 
(APC)79,82,83. They present antigens to naive B cells within the GC and are therefore 
responsible for the positive selection of antigen-specific B cells82. Besides presenting antigen 
to naïve B cells, FDC with bound antigen are also involved in the reselection process of 
already antigen-specific memory B cells that are frequently homing back to the GC during the 
secondary immune response84. We could show that FDC are directly involved in the infection 
of memory B cells with EBV85. FDC bind EBV via complement receptor 2 (CR2) and 
presents the virus within the GC. During the positive selection process, EBV is then 
transferred from the FDC preferentially to memory B cells. The route by which EBV initially 
enters the GC might be through plasma cells, which were also shown to home to the GC86. 
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3.6. B cell homeostasis and EBV 
The mucosal immune system can be divided into inductive and effector sites. In 
inductive sites, antigens sampled from mucosal surfaces stimulate cognate naïve T and B 
lymphocytes. In effector sites the effector cells perform their action after extravasation and 
differentiation54,87-89. Inductive sites for mucosal immunity consist of organized mucosa-
associated lymphoid tissue (MALT) as well as local and regional draining lymph nodes 
(LNs), whereas the effector sites consist of distinctly different histological compartments, 
including lamina propria (LP) of various mucosae, stroma of exocrine glands, and surface 
epithelia. MALT structures resemble LNs with B-cell follicles, intervening T-cell areas, and a 
variety of antigen-presenting cells (APCs), but they lack afferent lymphatics87. 
Although the gastrointestinal-associated lymphatic tissue (GALT) is the largest and 
best defined part of MALT, other potentially inductive sites for mucosal B-cell responses are 
bronchus-associated lymphoid tissue (BALT) and nasopharynx-associated lymphoid tissue 
(NALT) – in humans particularly the unpaired nasopharyngeal tonsil (often called adenoids) 
and the paired palatine tonsils88. The latter organs make up most of Waldeyer’s pharyngeal 
lymphoid ring and may play a major role for mucosal immunity in human airways. Besides 
that, NALT is widely accepted to be the portal of entry of EBV. It is in the tonsils, where 
EBV first encounters and infects B cells. 
Previously, we reported that memory B cells are susceptible to EBV infection, if they 
originate from NALT46. Memory B cells generated in other lymphatic organs do not express 
the required amount of β1 integrin, therefore leading to inefficient binding and entry of EBV. 
This implies that EBV, even though it can be employed as a tool to transform memory B cells 
secreting antibodies against respiratory antigen which led to affinity maturation in the NALT, 
transformation of memory B cells selected in non-NALT by antigen is not feasible. 
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Figure 4. Model of differential susceptibility of memory B cells from diverse lymphatic tissues to EBV 
infection. EBV enters the body mainly via the saliva and penetrates the oral mucosal epithelium to gain access to 
the B cell-rich areas of the NALT, including tonsils. Here, EBV is able to directly infect memory B cells that 
have been generated within the NALT. Other lymphatic organs may eventually also be exposed to EBV, even 
though memory B cells generated in these organs are less susceptible to EBV infection.  
3.7. Cofactors in the genesis of EBV-associated malignancies 
Several cofactors have been associated to the formation of EBV-harboring 
malignancies. The two most important are malaria and HIV.  
3.7.1. Human Immunodeficiency virus (HIV)  
In the setting of a progressing HIV infection accompanied by loss of CD4+ T cells, 
EBV-harboring brain lymphoma are common and the leading cause for lymphomagenesis in 
HIV-patients22. The theory holds that the lacking immune control through CD4 and CD8+ T 
cells leads to an unhampered expansion of EBV-infected B cells, driven by the expression of 
the ‘growth program’ of EBV.  
3.7.2. Plasmodium falciparum malaria 
The role of malarial infection in the pathogenesis of eBL was supposed for the 
geographical co-incidence of the two diseases. It is generally thought that the association 
between malaria and BL arises from a combination of immunosuppression and B-cell 
activation3,4,90,91. For example, cytotoxic T-cell mediated control over the outgrowth EBV-
infected B cells is impaired during acute malaria infection, and it has been found that 
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peripheral EBV loads may be five times higher during acute malaria compared to levels 
observed during convalescence or in healthy individuals92. EBV loads are generally higher in 
areas of holoendemic malaria compared to areas where malaria is sporadic, and show 
increased persistence in children with a history of severe rather than mild malaria, possibly 
owing to higher viral reactivation. Endemic BL also develops at a later age in individuals who 
have migrated from malaria-free high altitude areas to lower, malaria-endemic areas.  
In support of these findings, it has recently been found that the malarial parasite 
Plasmodium falciparum can directly activate B cells via a cysteine-rich interdomain region 1α 
(C1DR1α) on the P. falciparum erythrocyte membrane protein 1 (PfEMP1), which binds to 
surface Ig93. The activation of B cells by CIDR1α and subsequent protection from apoptosis 
has been postulated to play a role in enhancing survival of GC B cells bearing oncogenic 
mutations. In addition to the activation of B cells, it is possible that proliferation of B cells is 
enhanced by IL-10. Serum levels of this cytokine are raised in children suffering from acute 
P. falciparum malaria compared to healthy controls2,94. Protective immunity is only acquired 
following several years of exposure to the malarial parasite P. falciparum, and the intervening 
immunosuppression in malaria endemic areas may alter the regulation of EBV-positive B 
cells. 
Another recent finding identified that the malaria pigment hemozoin specifically binds 
DNA and continuously stimulates TLR995. This chronic innate immune stimulation may be 
one of the key factors governing malignant transformation. 
 
 
 
Figure 5. Geographic distribution of EBV-associated malignancies (left) and endemic P. falciparum 
malaria (right). 
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3.8. Innate immunity and Epstein-Barr virus 
Interactions between pathogens and the host they infect are multifactorial. Innate 
immunity mediates direct antimicrobial effects at the earliest times of primary infections, 
while slower adaptive and humoral immune responses are being expanded and activated. 
Innate immunity also delivers important immunoregulatory effects to shape downstream 
immune responses. Thus, the innate immune system is prepared to act as a first line for 
sensing infection, to unleash protective defense mechanisms mediated through a high 
proportion of preexisting cells, and to both direct and support other protective responses.  
Toll-like receptors (TLR), the major receptor type of the innate immune system, are a 
family of transmembrane proteins each of which recognizes specific microbial pathogen-
associated molecular patterns (PAMPs) to sense infection and then responds by triggering 
specific cellular responses96-99. Members of the TLR family of molecules, now numbering in 
excess of ten, bind to various microbial products that can be distinguished as nonself100. 
Besides being the first line of defense through the activation of cytokine production, 
TLRs were also shown to shape the humoral immune response either by activating somatic 
hypermutation thereby enhancing the efficiency of the GC reaction or by modulating the 
process of class-switch recombination favoring the generation of IgG-bearing memory B 
cells99. 
Most TLR signaling pathways require cellular adapter proteins to start a cascade of 
phosphorylation-dependent events ultimately culminating in the activation of key 
transcription factors such as nuclear factor (NF)-κB, JNK or AP-196. These are then 
responsible for the transcription of an array of proinflammatory cytokines and chemokines. 
Albeit only six adapter proteins are known to play a role in TLR activation, the response to 
TLR engagement are multifaceted implying that additional factors besides the type of adapter 
protein are required to shape TLR signaling101. 
Even though TLRs have initially been linked to antiviral effects, recent data suggest, 
that several members of the herpesvirus family modify the TLR signaling pathways to 
maintain their latent infection or evade recognition by other immune cells. 
Some EBV viral products have the ability to manipulate the host cellular TLR 
signaling pathways during latent or lytic phases. Such deregulated signaling by viral products 
contributes to malignant cell proliferation, survival and viral expansion. 
EBV latent membrane protein 1 (LMP1) activates the NF-κB pathway102-105. The 
LMP1 C-terminal cytoplasmic tail contains two distinct functional domains, C-terminal 
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activation regions 1 and 2 (CTAR1 and 2). Each CTAR1-TRAF2 and CTAR2-TRADD 
complex links to the IKK–NIK–NF-κB pathway106,107. These unscheduled activations of the 
NF-κB pathway by viral products are required for virus-induced cellular transformation and 
cell survival. 
Furthermore, LMP1 induces IRF4 expression, an Interferon regulatory factor family 
member that negatively modulates TLR-mediated IRF-5 activation by competing with IRF-5 
for interaction with MyD88108. This leads to upregulation of MyD88 and TLR7 followed by 
increased cellular proliferation. 
EBV latent membrane protein 2A (LMP2A) has an N-terminal cytoplasmic region 
containing eight tyrosine residues, which function as the immunoreceptor tyrosine-based 
activation domain (ITAM) motif109. The phosphorylated ITAM region recruits Src-type 
tyrosine kinases, and this ITAM signalsome-mediated ERK-activation also stimulates the c-
Jun/AP-1 pathway110. 
In addition, non-protein products from EBV, EBER1 and 2 are shown to affect host 
cell signaling. EBER1 and 2 are non-translated viral small RNA abundantly expressed in 
EBV latently infected cells. EBER activate the NF-κB and IRF3 pathways through 
association with RIG-I111,112.  
Besides latent EBV gene products, also lytic EBV genes impact the signaling induced 
downstream of TLRs. ZEBRA, the protein encoded by the immediate-early gene BZLF1 of 
EBV is on the one hand inducing NF-κB translocation into the nucleus113, but is also able to 
inhibit binding of NF-κB to responsive promoters114. 
All of the above-mentioned cellular signaling molecules and transcription factors are 
also activated downstream of TLR activation. These data show that EBV by itself modulates 
the innate immune system thereby preventing immune recognition of EBV-infected cells. 
Furthermore, several pathways of the innate immune system are known to influence the 
balance between EBV latent and lytic infection. Signaling through TLR9 ultimately leading to 
the sequestration of IL-12 and IFN-γ downregulates EBV lytic infection through a so far 
unknown mechanism115. Besides that, it could be shown that TLR signaling impacts the EBV-
associated growth transformation of B cells116-120. 
Introduction 
 
Figure 6. Mutual influence of innate, adaptive immunity and EBV infection in B cells. Signaling pathways 
regulated downstream of the innate immune receptors of the Toll-like family or the B-cell receptor are also 
frequently modulated by EBV latency and lytic proteins. Especially the transcription factor NF-κB, which is 
activated by TLRs could be shown to have a regulatory loop with an EBV immediate-early protein ZEBRA. 
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4. Subject of investigation 
Due to the fact that 40 years after the initial discovery of EBV, an exact mechanism, 
explaining the EBV persistence and lymphomagenesis are only addressed partially, we aimed 
at dissecting the pathways EBV uses to enter the host and how EBV may serve as an 
oncogenic factor/cofactor in the development of EBV-associated lymphomas. 
To answer these questions, we formulated the following working hypothesis: 
1. Memory B cells, the main reservoir of EBV in vivo are directly susceptible to EBV 
infection 
2. EBV preferentially infects those memory B cells that originate in the nasopharynx-
associated lymphatic tissue, the portal of entry of EBV 
3. The Follicular Dendritic cell network of the tonsils facilitates infection of memory B 
cells by EBV  
4. Memory B cells retain their characteristic gene expression profile following EBV 
growth transformation rendering them a more likely target for EBV primary infection 
than naïve B cells 
5. Immune activation, which is a prerequisite for the generation of EBV-associated 
lymphomas in vivo, influences the balance of EBV latent and lytic infection leading to 
an increased likelihood of EBV-associated lymphomagenesis 
6. Toll-like receptors, which are initiating a MyD88-dependent NF-κB activation are 
expressed at distinct stages during B cell maturation and are responsible for increased 
plasma cell immunoglobulin production 
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5. Results 
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5.1. Distinct ex vivo Susceptibility of B-cell subsets to EBV infection 
According to Differentiation Status and Tissue origin 
Marcus Dorner, Franziska Zucol, Christoph Berger, Rahel Byland, Gregory T. Melroe, 
Michele Bernasconi, Roberto F. Speck, and David Nadal (2008) J. Virol., 82:4400-12. 
 
Abstract 
Epstein-Barr virus (EBV) uses tonsils as the portal of entry to establish persistent 
infection. EBV is found in various B-cell subsets in tonsils but exclusively in memory B cells 
in peripheral blood. The in vitro susceptibilities of B-cell subsets to EBV infection have been 
studied solely qualitatively. In this work, we examined quantitatively the in vitro 
susceptibilities of various B-cell subsets from different tissue origins to EBV infection. First, 
we established a centrifugation-based inoculation protocol (spinoculation) that resulted in a 
significantly increased proportion of infected cells compared to that obtained by conventional 
inoculation, enabling a detailed susceptibility analysis. Importantly, B-cell infection occurred 
via the known EBV receptors and infected cells showed EBV mRNA expression patterns 
similar to those observed after conventional inoculation, validating our approach. Tonsillar 
naïve and memory B cells were infected ex vivo at similar frequencies. In contrast, memory B 
cells from blood, which represent B cells from various lymphoid tissues, were infected at 
lower frequencies than their naïve counterparts. Immunoglobulin A (IgA)-positive or IgG-
positive tonsillar memory B cells were significantly more susceptible to EBV infection than 
IgM-positive counterparts. Memory B cells were transformed with lower efficiency than 
naïve B cells. This result was paralleled by lower proliferation rates. In summary, these data 
suggest that EBV exploits the B-cell differentiation status and tissue origin to establish 
persistent infection. 
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5.2. Integrin expression determines the susceptibility of memory B cell 
subpopulations to EBV infection 
Marcus Dorner, Franziska Zucol, Walter Bossart, Stephan Haerle, Rahel Byland, Christoph 
Berger, Roberto F. Speck and David Nadal, manuscript in preparation 
 
Abstract 
The Epstein-Barr virus uses the tonsils as portal of entry to establish life-long 
persistence within the memory B cell pool. In vitro infection of memory B cells leading to the 
transformation and subsequent immortalization of the cells was employed to show that the 
resulting lymphoblastoid cell lines showed antigen-specificity for respiratory antigen. 
Nevertheless, attempts in selecting for non-respiratory antigen-specificity were so far 
unsuccessful. In this work, we show that memory B cells that were selected via affinity 
maturation within the nasopharynx-associated lymphatic tissue are susceptible to EBV 
infection, whereas those that were selected in other secondary lymphatic organs are not. This 
preferential infection of NALT memory B cells in turn leads to the exclusive transformation 
of memory B cells with specificity against respiratory pathogens, thereby explaining, why 
antigen-specific cell lines reacting to non-respiratory antigen could not be generated in the 
past. The differential infection susceptibility of NALT and non-NALT memory B cells is 
mediated by the high expression of α5β1 integrin on memory B cells from the NALT, 
compared to the α5β1low memory B cells from other lymphatic tissues. EBV uses α5β1 integrin 
as an attachment factor to facilitate more efficient entry into memory B cells. Upon binding to 
the integrins, EBV initiates a cellular signalling cascade via c-Src and PI3 kinases to activate 
focal adhesion kinase ultimately leading to enhanced actin filament depolymerization. This in 
turn enables a more efficient EBV entry process compared to α5β1low memory B cells. 
 24
Results 
5.3. Epstein-Barr Virus Triggers Integrin and Focal Adhesion Kinase-
Mediated Signalling During Binding to and Infection of Epithelial 
Cells 
Rahel Byland, Marcus Dorner, Michele Bernasconi, David Nadal and Roberto F. Speck, 
manuscript in preparation 
 
Abstract 
The γ-herpesvirus Epstein-Barr (EBV) preferentially infects human B and epithelial 
cells and is associated with a pathogenic role in neoplasia of both types. While EBV infection 
of B cells is well-characterized, mechanisms of entry into epithelial cells are poorly 
understood. Binding of the EBV glycoprotein BMRF-2 to integrins of the β1 family plays a 
crucial role in the epithelial cell infection process. Nevertheless, the mechanisms by which 
integrins facilitate EBV entry are not defined. We investigated the events triggered by EBV 
binding to epithelial cells in a tissue culture system using the model cell line AGS. We 
demonstrate that binding of EBV to integrin and subsequent intracellular signalling are crucial 
for augmenting EBV infection and that EBV triggers signalling events leading to activation of 
focal adhesion kinase (FAK). FAK and its downstream effectors PI3K and c-Src were 
essential for enhancing EBV infection as well as for EBV-mediated changes in the 
cytoskeleton. EBV binding induced activation of the regulatory small GTPase RhoA leading 
to a disassembly of cortical actin and the formation of actin stress fibres; furthermore, EBV 
caused a reorganization and stabilization of microtubuli. These data suggest pathways that 
may facilitate EBV entry into epithelial cells and further define the EBV-host interaction. A 
deeper understanding of such mechanisms is key for understanding EBV biology and notably 
pathogenesis of EBV-associated diseases.  
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5.4. Follicular Dendritic Cell-B Cell Clusters facilitate the transfer of 
Epstein-Barr virus to the memory B cell pool 
 
Marcus Dorner, Marianne Tinguely, Franziska Zucol, Christoph Berger, David Nadal, 
manuscript in preparation 
 
Abstract 
The Epstein-Barr virus (EBV) is known to exclusively persist in peripheral blood 
memory B cells following primary infection. This strict tropism for B cells is only eminent for 
non-lymphoid systems, whereas in the mucosal-associated lymphoid tissue of the Waldeyer’s 
Ring, EBV is also found in cell of non-B-lineage. The life-cycle of EBV holds that it infects 
B cells at various differentiation stages, i.e. naïve, germinal center and memory B cells. After 
recirculation of the EBV-infected memory B cells to the tonsil and consecutive activation by 
an apt antigen, the terminally differentiated EBV-positive Plasma cell will reactivate EBV 
and shed newly formed virions. Direct viremia of EBV in contrary is hampered by the fast 
and efficient recognition of EBV lytic cycle antigens by EBV-specific CD8+ T cells. We now 
report for the first time, that EBV utilizes the antigen-presenting properties of follicular 
dendritic cells to transfer to B cells establishing persistence without the necessity of free 
virus. These findings demonstrate how EBV spreads within the host and reveals an additional 
reservoir for EBV outside the B cell compartment. 
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5.5. Naïve and memory B cells show distinct gene expression profiles 
following EBV transformation  
 
Marcus Dorner, Franziska Zucol, Christoph Berger, Michele Bernasconi, Roberto F. Speck, 
and David Nadal, manuscript in preparation 
 
Abstract 
The Epstein-Barr virus is known to infect human naïve and memory B cells ex vivo, 
showing preferential infection of memory B cells originating within the nasopharynx-
associated lymphatic tissue, the portal of entry of EBV. Even though many reports 
investigating in vivo and ex vivo EBV infections exist, the initial target cell for EBV in vivo 
could not yet be identified. As primary infection of EBV cannot be investigated in vivo due to 
lacking small-animal models and primary infection with EBV in humans is rarely detected 
due to the long incubation period until the onset of clinical symptoms of Infectious 
mononucleosis we challenged the question, whether the target B cell subpopulation could be 
identified by comparison of the gene expression signatures of different B cell subpopulations 
following ex vivo infection with EBV. Indeed, we found striking differences in global gene 
expression when comparing resting naïve B cells and EBV transformed naïve B cells to their 
memory counterparts. EBV transformation initiates a pronounced upregulation of cancer-
associated genes and downregulates pro-apoptotic regulators. In contrast, this dramatic 
change of gene expression profile is absent in memory B cells, thereby indicating that EBV 
could use memory B cells as an initial reservoir, as naïve B cells would more likely lead to 
tumor formation or cell death due to apoposis. 
 
Experimental layout 
Naïve and memory B cells were isolated from tonsils as described previously77. Resting naïve 
and memory B cells were subjected to immediate isolation of mRNA, or were infected with 
EBV by spinoculation and allowed to transform on an autologous B cell-depleted feeder layer 
for 4 weeks prior to isolation of mRNA. Amplification of cRNA, labelling and hybridization 
to Affymetrix U133 Plus 2 microarray slides was performed at the Functional Genomics 
Center Zurich. 
 
 
 27
Results 
Results 
We aimed at dissecting the global gene expression changes induced by EBV growth 
transformation of isolated naïve and memory B cells. For this reason, we isolated naïve and 
memory B cells from tonsils and either used them for mRNA extraction directly or 4 weeks 
after EBV growth transformation. Comparing the differences in global gene expression in 
response to EBV transformation between naïve and memory B cells, we were able to identify 
genes regulated exceptionally in naïve or memory B cells. Whereas memory B cells 
preferentially express genes inhibiting extensive cell cycle progression and B cell activation, 
naïve B cells upregulate a wide panel of genes involved in proliferation and cell cycle 
progression (Table 5). Furthermore, naïve B cells express a whole pathway associated with 
tumor growth, tumor vascularisation and lymphomagenesis upon transformation with EBV 
(Figure 7), whereas this pathway is nearly completely absent in EBV transformed memory B 
cells (Figure 8). 
 
Table 5. Genes regulated exclusively in naïve B cells following EBV transformation 
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Figure 7. Regulation of Cancer-associated genes in naïve B cells following EBV transformation. 
Downregulated genes are depicted in green, upregulated genes in red. Analysis was done using Genespring 9.0 
and Ingenuity Pathway Analysis. Statistics were performed using nonparametric t-tests assuming uneven 
variencies and a cutoff of p<0.01. 
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Figure 8. Regulation of Cancer-associated genes in memory B cells following EBV transformation 
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5.6. Immune activation suppresses initiation of lytic Epstein-Barr virus 
infection 
Kristin Ladell*, Marcus Dorner*, Ludwig Zauner, Christoph Berger, Franziska Zucol, 
Michele Bernasconi, Felix K. Niggli, Roberto F. Speck, David Nadal (2007) 
Cell. Microbiol. 9:2055–2069.  
* authors contributed equally 
 
Abstract 
Primary infection with Epstein-Barr virus (EBV) is asymptomatic in children with 
immature immune systems but may manifest as infectious mononucleosis, a vigorous immune 
activation, in adolescents or adults with mature immune systems. Infectious mononucleosis 
and chronic immune activation are linked to increased risk for EBV-associated lymphoma. 
Here we show that EBV initiates progressive lytic infection by expression of BZLF-1 and the 
late lytic genes gp85 and gp350/220 in cord blood mononuclear cells (CBMC) but not in 
peripheral blood mononuclear cells (PBMC) from EBV-naive adults after EBV infection ex 
vivo. Lower levels of proinflammatory cytokines in CBMC, used to model a state of minimal 
immune activation and immature immunity, than in PBMC were associated with lytic EBV 
infection. Triggering the innate immunity specifically via Toll-like receptor-9 of B cells 
substantially suppressed BZLF-1 mRNA expression in acute EBV infection ex vivo and in 
anti-IgG-stimulated chronically latently EBV-infected Akata Burkitt lymphoma cells. This 
was mediated in part by IL-12 and IFN-γ. These results identify immune activation as critical 
factor for the suppression of initiation of lytic EBV infection. We hypothesize that immune 
activation contributes to EBV-associated lymphomagenesis by suppressing lytic EBV and in 
turn promotes latent EBV with transformation potential. 
 
 
Author contributions: MD performed the experiments described in Figures 1, 2, 3, 6 D-F and 7 and designed the 
experiments outlined in Figure 6D-F and 7. 
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5.7. The Toll-like receptor (TLR)10 mRNA expression pattern at distinct 
B-cell developmental stages is different from that of TLR1-TLR9 
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Abstact 
Toll-like receptors (TLRs) are key receptors of the innate immune response and show 
cell subset specific expression. We hypothesized that expression and function of TLRs are 
tailored to distinct stages of B-cell development. We investigated the mRNA expression of 
TLR genes in B-cells at distinct developmental stages. Hematopoietic stem cells (HSC) and 
plasma cells were unique by their unrestricted expression of TLR1-TLR9, but absence of 
TLR10. Triggering plasma cells with TLR ligands augmented immunoglobulin production. 
By contrast, naïve and memory B-cells lacked TLR3, TLR4 and TLR 8 but expressed all 
other TLRs. Likewise the expression pattern observed in malignant cells was largely retained 
compared to their non-transformed developmental stage counterpart. Given the property of 
TLR1-TLR9 to augment immunoglobulin production upon pathogen recognition, the presence 
of TLR10 on B-cells rather than plasma cells and HSC and the lack of a TLR10 agonist may 
point to a unique function of TLR10 including homing. 
 
 
Author contributions: MD performed the experiments described in Figures 1, 3 and 4 and designed the 
experiments. 
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As we could show, memory B cells originating from the lymphatic tissue of the 
Waldeyer’s ring are directly susceptible to EBV infection and contribute to the rapid 
establishment of persistence after primary infection.  
The direct infection of antigen-selected memory B cells holds the advantage, that these 
cells are readily stimulated via cognate antigen. Previous models based on the initial infection 
of naïve or germinal center B cells with EBV inevitably lead to the generation of memory B 
cells that do not recognize apt antigen. Therefore, these EBV-infected “phenotypic” memory 
B cells fail to undergo terminal differentiation to plasma cells which in turn leads to the 
inability of EBV to reactivate lytic replication. Another advantage of the model of a direct 
infection of memory B cells with EBV is that, upon antigenic stimulation, one part of the 
memory B cells will undergo terminal differentiation whereas the other part will start rapid 
proliferation ensuring further persistence of EBV within the pool of long-lived memory B 
cells. 
Furthermore, we could show that only those memory B cells that have been generated 
by respiratory antigen within the Waldeyer’s ring tissue are susceptible to EBV infection and 
transformation. As the tonsils are the portal of entry of EBV, the virus may have adapted to 
infecting specifically those memory B cells that are specific for respiratory antigen or 
pathogens. We could also identify the cellular factor restricting the infection susceptibility of 
non-NALT memory B cells to be β1 integrin. This has already been shown in the past to play 
a role in the infection of epithelial cells by EBV. Furthermore, integrins are known as homing 
receptors specifically guiding the cells to distinct lymphatic tissues. Thereby, EBV uses only 
those memory B cells that will home back to the tonsils in response to a respiratory infection 
as reactivation of EBV within the tonsil will facilitate easy spread of EBV to new hosts. 
As we could show a direct contribution of memory B cells from the tonsil to EBV 
persistence, we challenged the question, how infectious EB virions might be delivered to 
them within the tonsil.  Since lytic replication of EBV in plasma cells would elicit a fast 
immune response mainly by CD4 and CD8 T cells, we investigated the role of possible 
bystander cells in the infection of B cells with EBV. To evade this, EBV makes use of the 
Follicular Dendritic cell network present within the GC. EBV is able to bind to FDC which 
then in turn transfer the virus preferentially to memory B cells homing back to the GC for 
antigenic reselection.  
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Figure 9. Proposed model for the establishment of EBV persistence and the origin of EBV-associated 
lymphoma. EBV exploits the normal B cell differentiation pathway by taking the role of foreign antigen. After 
binding to intraepithelial dendritic cells within the tonsil121,122, the DC home to the secondary lymphoid follicle. 
Here, two possibilities exist finally leading to EBV infection of B cells. (1) In the course of positive selection 
within the GC, EBV may be transferred from the DC to a naïve or GC B cell or (2) EBV persists on the DC and 
is then transferred to a memory B cell that is homing back to the GC for antigen-reselection. Both models 
explain why continuous stimulation of EBV-specific CTL does not occur within the tonsil as they do not have 
the necessity for free viral particles. 
 
This finding opens a new field for targeted drug treatment of IM, as influencing a 
potential reservoir for EBV by blocking attachment of EBV to FDC might limit fast 
expansion of EBV-infected B cells, thereby limiting the immune hyperactivation observed 
during IM. 
Additionally, we challenged the question which B cell subpopulation is the initial 
target for EBV by comparing the genome-wide gene expression profiles of naïve and memory 
B cells following EBV transformation and could identify a panel of cancer-associated and 
apoptosis-related genes that are upregulated exclusively in naïve B cells. In contrast, memory 
B cells downregulate genes that are associated with extensive proliferation and further 
differentiation. These results allow the speculation, whether naïve B cells are playing a role in 
the establishment of EBV persistence in vivo at all or whether EBV-infected naïve B cells 
undergo immediate apoptosis to prevent oncogenic transformation. 
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Dissection of the possible pathways by which EBV establishes persistence within the 
host enabled us to move on to a closer examination of how EBV could contribute to its 
associated malignancies, especially those that are also associated with increased immune 
activation.  
As EBV-associated Burkitt’s lymphoma is closely associated with endemic malaria, 
which leads to a chronic stimulation of the immune system, we tested, whether the initial 
immune activation status has an impact on EBV persistence.  
We were able to demonstrate that a higher immune activation status, mainly due to 
elevated levels of interleukin-12 and interferon γ leads to an inhibition of EBV lytic 
replication. Furthermore, stimulation of TLR9, which is also constitutively triggered during 
chronic malaria, resulted in an IL-12/IFN-γ-dependent inhibition of EBV replication. This 
clearly demonstrates that the innate immune system which senses a wide array of different 
pathogens directly influences the life-cycle of EBV resulting in a more restricted latency of 
EBV-infected B cells. A Latent infection of EBV-infected B cells in turn is mandatory for the 
development of EBV-associated malignancies such as Burkitt’s lymphoma.  
Thus, our findings regarding the differential susceptibility of B cell subpopulations to 
EBV infection and the impact of immune activation of EBV life-cycle serve to a better 
understanding of EBV-associated lymphomagenesis.  
The next milestones that need to be further determined are on the one hand, whether 
the direct infection of antigen-specific memory B cells by EBV by the highly efficient 
spinoculation protocol holds the key to the development of a patient- and pathogen-specific 
antibody therapy, as EBV-transformed memory B cells could be generated, secreting 
antibodies with specificity for the whole pool of antigens the host encountered so far.  
The second important step would include validation of α5β1 integrin or the so far 
unidentified attachment factor of EBV to FDC as a drugable target for vaccination or even 
treatment against EBV persistence. Blocking the entry of EBV either into the whole B cell 
pool or specifically into memory B cells holds the potential to prevent the establishment of 
EBV persistence within the memory B cell pool even after seroconversion. 
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Abstract 
The Epstein-Barr virus uses the tonsils as portal of entry to establish life-long 
persistence within the memory B cell pool. Even though it is generally believed that 
transmission of EBV occurs via saliva, the exact mechanisms of how EBV gains access to 
the memory B cell pool is still unclear. In this work, we show how EBV selectively infects 
only memory B cells that were generated within the nasopharynx-associated lymphatic 
tissue ex vivo, with memory B cells from other lymphatic organs being less susceptible to 
infection. Furthermore, we demonstrate that memory B cells that were selected via 
affinity maturation within the nasopharynx-associated lymphatic tissue are susceptible 
to EBV infection, as they express high levels of α5β1 Integrin, which, upon binding of 
EBV, delivers signals ultimately leading to enhanced EBV entry via phosphorylation of 
FAK, c-Src, PI3K p85α, cofilin and actin depolymerization. This preferential infection 
of NALT memory B cells in turn leads to the exclusive transformation of memory B cells 
with specificity against respiratory pathogens, thereby explaining, why antigen-specific 
cell lines reacting to non-respiratory antigen could not be generated in the past.
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Introduction 
The Epstein-Barr (EBV) virus is a ubiquitous human γ-herpesvirus associated with Burkitt’s 
lymphoma and post-transplant lymphoproliferative disease (Rickinson and Kieff, 2001). Even 
though primary infection with EBV during childhood is usually asymptomatic, adults may 
develop symptoms of infectious mononucleosis (IM) (Cohen, 2000). The acute phase of EBV 
infection, whether it is accompanied by IM or not leads to the establishment of life-long 
persistence of the virus within the B cell pool of the host (Babcock et al., 1998; Miyashita et 
al., 1997). The portal of entry of EBV is the lymphatic tissue of the Waldeyer’s ring, where 
EBV enters the tonsillar B cell-rich areas to establish latent infection (Berger et al., 2007). 
During the course of infection, EBV is able to infect B cells at all maturation stages, including 
naïve (Joseph et al., 2000; Thorley-Lawson and Babcock, 1999; Thorley-Lawson and Gross, 
2004), germinal center (GC) (Bechtel et al., 2005; Kuppers, 2005; Mancao et al., 2005) or 
memory B cells (Dorner et al., 2008; Ehlin-Henriksson et al., 2003; Kurth et al., 2000) within 
the tonsil. Depending on the differentiation of the B cells at the time-point of infection, the 
expression of latent EBV genes varies from nearly all EBV latent genes being expressed in 
naïve B cells to a very restricted expression in memory B cells (Babcock et al., 2000). After 
the EBV-infected memory B cells exit the lymphatic tissue of the tonsil and enter the 
peripheral circulation, EBV evades immune recognition by completely shutting down latent 
gene expression in resting memory B cells (Babcock and Thorley-Lawson, 2000; Miyashita et 
al., 1997). Only after the EBV-infected memory B cells home back to the tonsils and are 
activated through the recognition of an apt antigen, EBV reactivates from latency during the 
process of plasma cell differentiation (Laichalk and Thorley-Lawson, 2005).  
EBV has been used in the past to generate Lymphoblastoid cell lines secreting antibodies 
specific for respiratory pathogens such as influenza or SARS coronavirus (Lanzavecchia et 
al., 2006; Lanzavecchia et al., 2007; Simmons et al., 2007; Traggiai et al., 2004; Zhu et al., 
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2007). Recently, we could demonstrate that EBV preferentially infects memory B cells from 
tonsils, but not those from peripheral blood (Dorner et al., 2008). Memory B cells present 
within the peripheral blood exhibit specificities for both, respiratory and non-respiratory 
pathogens, thus resembling a mixture of memory B cells originating from the NALT and 
other lymphatic tissues (Brandtzaeg et al., 1999). In contrast, memory B cells from the tonsils 
are mainly generated by affinity-maturation to respiratory pathogens. 
Here we show that memory B cells originating from the NALT, the portal of entry of EBV are 
susceptible to EBV infection and growth transformation, thus giving raise to antibody-
producing LCLs with a specificity for respiratory pathogens. In contrast, memory B cells 
from other lymphatic tissue are not susceptible to EBV infection and transformation thereby 
explaining the absence of antibody production against non-respiratory pathogens. 
Furthermore, we identified the reason for this difference between memory B cells from 
distinct lymphatic tissues to be the presence or absence of α5β1 integrin. Absence of α5β1 
integrin on non-NALT memory B cells leads to decreased EBV infection and transformation. 
Even though described solely as an attachment factor for EBV on epithelial cells, we present 
data showing that also integrin-mediated signalling is essential for efficient infection of 
memory B cells with EBV. 
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Results 
Memory B cells originating from NALT are more susceptible to EBV infection and 
transformation than their counterparts from other lymphatic organs. 
Memory B cells are the main reservoir for EBV persistence in vivo and they are also 
susceptible to direct infection with EBV in vitro, even though there appear to be tissue-
specific differences (Babcock et al., 1998; Dorner et al., 2008). To investigate these 
differences in detail, we performed infection assays using spinoculation of high-titer EBV as 
previously described (Dorner et al., 2008).  
Memory B cells from tonsils, which are part of the Waldeyer’s ring forming the NALT, show 
the highest susceptibility to EBV infection with 75.8 ± 4.9 % of infected cells 24 hours post 
inoculation (Fig 1A). In contrast, memory B cells from peripheral blood, which is a mixture 
of memory B cells from all lymphatic compartments, could only be infected in 30.3 ± 13.6 % 
of cells. To dissect the distinct memory B cell subpopulations originating from NALT and 
non-NALT, we exploited the presence of L-selectin (CD62L) on memory B cells from NALT 
to distinguish between NALT and non-NALT-originating memory B cells (Brandtzaeg and 
Johansen, 2005). Tonsils, in which the NALT-originating memory B cells are generated, 
contain 81.6 ± 6.7 % CD19+CD27+CD62L+ NALT memory B cells indicating that only 19 % 
of the memory B cells have homed to the tonsil from different lymphatic organs (Fig. 1B). In 
contrast, only 21.5 ± 6.9 % of the CD19+CD27+ memory B cells express CD62L with over 79 
% of the memory B cells originating in non-NALT. 
Infection of memory B cells from tonsils and peripheral blood yielded a similar pattern of 
EBV infection. CD19+CD27+CD62L+ memory B cells from tonsils and peripheral blood 
showed a higher infection frequency (75.8 ± 5.0 % and 67.8 ± 7.9 %, respectively) compared 
to CD19+CD27+CD62L- memory B cells, which showed lower infection frequencies in tonsils 
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and peripheral blood (40.0 ± 7.0 % and 16.0 ± 4.7 %, respectively). EBV infection did not 
alter the expression pattern of CD62L (data not shown). 
 
EBV-associated transformation efficiency is higher in NALT memory B cells, enabling 
the generation of antibody-producing LCL against respiratory antigen. 
Efficient infection of memory B cells by EBV is a prerequisite to efficient generation of 
antibody-producing LCL. As the initial infection of CD62L- memory B cells originating from 
non-NALT is hampered, the transformation efficiency of these cells should also be lower 
compared to CD62L+ memory B cells from NALT. To address this question, we performed 
transformation assays using limiting dilutions of EBV-infected memory B cells from tonsils 
(majority CD62L+) and from peripheral blood (majority CD62L-) on autologous B cell-
depleted feeder cells (Fig. 2A). Memory B cells from tonsils exhibit a three-fold higher 
transformation efficiency compared to those from peripheral blood. Thus, the question arose, 
whether the low infection frequency leading to the low transformation efficiency of non-
NALT-originating memory B cells is also reflected by the antibodies produced from the 
associated LCLs. Vaccinations, which are routinely applied via intramuscular injection lead to 
an initial round of affinity maturation of B cells within the lymph nodes rather than the 
lymphatic tissue of the nasopharynx. We therefore chose tetanus toxoid (TT) as a model 
antigen, identifying the lymph-node-selected memory B cells within the peripheral blood. 
Detection of TT-specific memory B cells was performed using an enzyme-linked 
immunosorbent spot (EliSPOT) assay (Suzuki and Tagami, 2005) and identified high 
numbers of TT-specific memory B cells six days post immunization (Fig. 2B). Following 
EBV-associated transformation of the memory B cells from peripheral blood, antigen-
specificity against TT could not be detected. To further validate our data, we performed 
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ELISA detecting anti-TT antibodies verifying the results observed in the EliSPOT assays 
(Fig. 2B). Controls for these assays included donors that did not receive any TT vaccination. 
In contrast to immunizations, wild-type infection with respiratory pathogens that do not lead 
to systemic viremia are restricted to generating antigen-specific memory B cells within the 
lymphatic tissue of the Waldeyer’s ring. Thus, we chose measles wild-type infection as a 
potential source of NALT-originating measles-specific memory B cells from peripheral blood 
which were detected with a measles virus IgG ELISA. In healthy donors without booster 
vaccination, only background antibody titers were detectable, whereas the anti-measles IgG 
titer in booster vaccinated and wild-type measles virus infected individuals were greatly 
increased. Booster vaccination with measles virus vaccine should, as observed for TT, 
primarily lead to affinity maturation of B cells within axillary lymph nodes. Following EBV 
transformation of B cells of measles virus boosted donors, anti-measles IgG production was 
completely absent irrespective of the initial anti-measles IgG titer after immunization. In 
contrast, EBV transformed B cells from wild-type measles infected donors showed constant 
levels of antibody production indicating that affinity maturation in the NALT is mandatory 
for EBV to infect the antigen-specific memory B cell. 
 
The EBV-attachment factor α5β1 integrin is highly expressed on memory B cells from 
NALT. 
Next, we were interested in identifying potential candidates explaining the higher infection 
susceptibility of memory B cells from NALT compared to those of other lymphatic organs. 
Recently, it has been described that the integrin receptor family, especially the α3, αV, and β1 
subunits, might play an important role in EBV attachment to epithelial cells (Xiao et al., 2008; 
Xiao et al., 2007). This binding is facilitated via a novel EBV glycoprotein, BMRF2 (Xiao et 
al., 2007). 
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To identify, whether the differential susceptibility of memory B cells from NALT and non-
NALT might be due to dissimilar α5β1 integrin expression levels, we isolated memory B cells 
from tonsils and peripheral blood and subjected them to immunofluorescence staining and 
flow cytometry for α5β1 integrin. Immunofluorescence shows a weaker expression of α5β1 
integrin on memory B cells from peripheral blood compared to tonsils even though all cells 
express β1 integrin at low levels (Fig. 3A, B). Quantification of the β1 expression levels 
validated the findings observed in immunofluorescence with 95.1 ± 4.4 % and 83.6 ± 3.1 % of 
β1-positive memory B cells from tonsils and peripheral blood, respectively (Fig. 3C). 
Analysis of the mean fluorescence intensity of α5β1 integrin on these cells revealed, that 
memory B cells from tonsils express 8- to 10-fold more β1 integrin compared to those from 
peripheral blood (Fig. 3D). 
 
EBV binds to α5β1high memory B cells, thereby enhancing the infection susceptibility of 
NALT-originating memory B cells. 
Next, we addressed the question, whether EBV uses β1 integrin to attach to NALT-originating 
memory B cell as it does with epithelial cells. The B-cellular infection with EBV has been 
extensively studied, identifying two cellular receptors important for EBV binding and entry 
into B cells (Miller and Hutt-Fletcher, 1992; Spear and Longnecker, 2003; Speck et al., 2000). 
The main attachment factor for EBV on B cells is CD21 (CR2, C3R), which is a member of 
the complement receptor family. Binding of EBV to CD21 via the viral glycoprotein 
gp350/220 has been shown to induce receptor-mediated endocytosis. Within the endosomal 
compartment, a trimer of EBV glycoproteins consisting of gH, gL and gp42 binds to HLA 
class II. This interaction in turn triggers a pH-dependent membrane fusion of EBV with the 
endosomal membrane and allows nuclear transport of the capsid.  
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To test, whether EBV uses α5β1 integrins on NALT memory B cells for attachment, we 
performed blocking experiments using either antibodies blocking EBV binding to α5β1 
integrins or soluble recombinant β1 integrin to compete with EBV binding to cellular β1 
integrin. When using either anti- α5β1 blocking antibodies alone or in combination with anti-
CD21 blocking antibodies, a dose-dependent reduction of the EBV infection frequency could 
be observed in tonsillar memory B cells, but not in peripheral blood memory B cells (Fig. 4A, 
B). Blocking of CD21 alone or blocking of HLA class II molecules was also included as 
positive control and showed a significant reduction of EBV infection frequency for both 
CD21 and HLA class II. 
Additionally, recombinant soluble β1 integrin, either with or without additional inhibition of 
the EBV glycoprotein gp350/220, showed the same dose-dependent inhibition of EBV 
infection of memory B cells from tonsils, but not from peripheral blood (Fig. 4C, D). As 
positive control, we also included blocking of gp350/220 alone or in combination with 
limiting dilutions of anti-gp42 to also block EBV penetration of the endosomal membrane.  
Thereby, we could show by either blocking cellular β1 integrin or by competing the β1 
integrin with recombinant protein that EBV indeed uses them as attachment factors not only 
to epithelial cells, but also to NALT-originating memory B cells. 
 
Integrin signalling is facilitating EBV entry into NALT-originating memory B cells. 
Even though the requirement of EBV binding to epithelial cells for EBV infection could be 
shown, the participation of signalling events downstream of α5β1 integrin initiated through 
EBV binding and their contribution to EBV entry have not been elucidated. We therefore 
dissected the integrin signalling pathway following EBV binding (Hehlgans et al., 2007; Sixt 
et al., 2006). One of the initial steps in integrin signalling involves activation of focal 
adhesion kinase 397Tyr phosphorylation followed by downstream signalling through PI3K, c-
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Src kinases and cofilin to ultimately activate the depolymerization of the actin cytoskeleton 
(Hehlgans et al., 2007; Huveneers et al., 2007; Rose et al., 2007; Shi and Simon, 2006; Yee et 
al., 2008). To investigate, whether EBV itself activates integrin signalling thereby enhancing 
infection efficiency, we (i) longitudinally followed the phosphorylation status of FAK, PI3K 
and cofilin upon binding of EBV and (ii) treated isolated memory B cells from tonsils with 
inhibitors of c-Src, PI3 kinases or FAK activation prior to infection with EBV. Binding of 
EBV to integrins leads to a rapid upregulation of pFAK within 20 minutes, which is followed 
by phosphorylation of c-Src, PI3K and cofilin (Figure 5A). Furthermore, protrusions in the 
actin cytoskeleton are readily detectable in memory B cells when binding of EBV occurs 
(Figure 5B). Inhibition of signalling molecules downstream of integrins led to a marked 
reduction of EBV infection frequency compared to mock treated cells (Fig. 5C,D). In 
addition, we also induced actin depolymerization, which is normally activated via the integrin 
signalling pathway. This showed a significant increase of the overall infection frequency of 
memory B cells with all cells being susceptible to EBV infection. 
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Discussion 
In this work, we aimed at assessing the susceptibility of memory B cells from distinct 
secondary lymphoid organs to EBV infection and transformation and to identify cellular 
factors influencing EBV entry into these cells. Indeed, we found that memory B cells from the 
nasopharynx-associated lymphatic tissue are more susceptible to EBV infection than their 
counterparts originating from other lymphatic tissue. We could show this by distinguishing 
NALT-originating CD62L+ memory B cells from non-NALT-originating CD62L- memory B 
cells in the tonsils and peripheral blood before and after infection with EBV. This difference 
of NALT- and non-NALT memory B cells in susceptibility to EBV infection consecutively 
manifested in the transformation efficiency of memory B cells from tonsils and peripheral 
blood. The two-fold lower infection frequency of peripheral blood memory B cells compared 
to tonsillar memory B cells led to a 2- to 5-fold reduced transformation efficiency of 
peripheral blood memory B cells. This furthermore explains, why in the past, only memory B 
cells selected against respiratory antigen could be efficiently transformed with EBV for the 
production of monoclonal antibodies. This could also been shown by measuring the antigen-
specificity of the EBV-transformed peripheral blood memory B cells. Even though the 
transformation efficiency at the employed cell density was above 50%, no antigen-specificity 
for tetanus toxoid could be detected. As this antigen was not delivered via the NALT, 
memory B cells were generated against TT mainly within the axillary lymph nodes but not 
within the tonsils and therefore were part of the CD62L- memory B cell pool that is not 
infected with EBV efficiently.  
In contrast, memory B cells from donors that recently underwent wild-type measles virus 
infection, which mainly affects the respiratory tract, could be shown to retain their antigen-
specificity throughout the process of EBV transformation. Antigen-specificity was determined 
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using EliSPOT and Elisa using fresh blood from TT-vaccinated or measles virus-infected or 
healthy individuals as positive and negative controls, respectively.  
The mechanisms by which the susceptibility of cells to EBV infection is regulated have only 
been described for epithelial cells and B cells, as epithelial cells do not express the known B-
cellular receptors, CD21 and HLA class II, crucial for EBV entry. As memory B cells from 
distict lymphatic tissue express equal amounts of CD21 and HLA class II, respectively, the 
observed differences in infection susceptibilities of memory B cells from different lymphatic 
sites cannot be explained by differential expression levels of CD21 and/or HLA class II. 
Recently, it has been described that the family of integrin transmembrane rececptors may play 
a role in the attachment of EBV to epithelial cells. We therefore chose the most promising 
candidate, the α5β1 subunit of integrins to further investigate, whether this receptor is also 
expressed on memory B cells. Indeed, we found that, even though all memory B cells 
expressed α5β1 integrin irrespective of the origin, memory B cells from tonsils expressed α5β1 
integrin at 10-fold higher levels compared to their counterparts from peripheral blood. As 
blocking of α5β1 integrin by using either blocking antibodies or the recombinant extracellular 
domain showed a dependence of EBV entry into memory B cells, we show for the first time, 
that the EBV glycoprotein BMRF2 - α5β1 integrin interaction is required and responsible for 
the distinct infection susceptibilities of memory B cells. 
The binding of EBV BMRF2 to α5β1 integrin induces signalling through crosslinking of α5β1 
leading to the activation of the downstream target focal adhesion kinase, which in turn 
activates PI3 kinases and c-Src. This in turn leads to activation of actin depolymerization 
which we could show to have a benefitial effect on EBV internalization by Cytochalasin D 
activation of actin depolymerization. 
Our data clearly demonstrate that EBV itself, via its glycoprotein BMRF2, determines the 
specificity for infection of memory B cells from different lymphatic tissue, preferentially 
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infecting memory B cells originating in the tonsil, the portal of entry of EBV. The inefficient 
infection of memory B cells from other lymphatic tissue than the NALT is furthermore 
reflected by a 2- to 5-fold reduced transformation capacity and the inability of memory B 
cells specific for non-respiratory antigen to undergo EBV-associated transformation. These 
findings also potentially shed light on why EBV-associated Burkitt’s lymphoma and Oral 
hairy leukoplakia are most frequently found to originate from regions of the NALT. If the 
infection frequency of NALT memory B cells is two fold higher than that of non-NALT 
memory B cells, these cells are also more likely to develop oncogenic mutations in response 
to the EBV infection. 
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Materials & Methods 
Cell culture and virus 
All cells were maintained in RPMI1640 supplemented with 10% FBS, 1% L-Glutamine, 1% 
Penicillin/Streptomycin, 1x Sodium pyruvate and 1x non-essential amino acids. B27 cells 
containing a BMRF2 knock-out EBV were kindly provided by Sharif Tugizov (…..). For 
virus production, the B95.8EBfaV-GFP cell line or the B27 BMRF2 ko cell line were used 
and cells were cultivated for 4 days at a cell density of 106 cells/mL in the presence of 50 
ng/mL 12-O-tetradecanoylphorbol 13-acetate (TPA). Following centrifugation of cells for 
300xg for 10 minutes and filtration of the supernatant through a 0.45μm membrane filter, 
supernatants were centrifuged for 2 hours at 17.000 rpm at 4°C to pellet EBV. The resulting 
pellet was then resuspended in TB-Sal buffer to obtain a concentration of 10 mg total protein 
per mL. Inactivation of EBV was performed either by heat-inactivation at 65°C for 1 hour or 
by UV-irradiation (254 nm, 1500 J…..). 
 
Antibodies and chemicals 
The used antibodies against CD19, CD27, CD29 and CD62L were purchased from BD 
Biosciences. The tetanus toxoid antigen, the anti-measles virus serum and the anti-tetanus 
antibody were supplied from the National Institute of Biological Standards and Control. The 
Tetanus vaccination Tetanol® Pur was from Novartis and the measles vaccination M-M-
RVaxPro® was from Sanofi-Pasteur. 
The measles virus antigen was a previously described B cell receptor epitope 
peptide{Zvirbliene, 2007 #671} purchased from Eurogentec.  
The function blocking antibody against α5β1 integrin and EBV gp350/220 were from Abcam, 
the soluble recombinant β1 integrin was from Thermo Scientific and the blocking antibodies 
against CD21 and HLA-DR,DP,DQ were purchased from Biolegend. The blocking antibody 
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against EBV gp42 (clone F2.1) was kindly provided by Dr. Hutt-Fletcher. The chemical 
inhibitors PP2, Wortmannin, Cytochalasin D and AG-82 were from Calbiochem and Ly-
294002 was from Sigma-Aldrich. Antibodies detecting either pY397 FAK or total FAK were 
from BD Biosciences. Antibodies detecting pY416 c-Src, total c-Src, pY458 pI3K p85α, total 
PI3K p85α, pS3 cofilin, total cofilin and all HRP-conjugated secondary antibodies were from 
Cell Signalling (………). 
 
Isolation of cells 
Human mononuclear cells were isolated from tonsils obtained from EBV-seronegative donors 
undergoing routine tonsillectomy and from peripheral blood of EBV-seronegative donors. 
Tonsillar mononuclear cells were prepared as previously described. Briefly, tonsils were 
disintegrated using a scalpel and the cell suspension was passed through a 70 μm cell strainer. 
After washing the cells with PBS, mononuclear cells were isolated by Ficoll-Paque density 
gradient centrifugation. 
Mononuclear cells from peripheral blood were also isolated by Ficoll-Paque density gradient 
centrifugation.  
Further separation of mononuclear cells into different lineages or differentiation stages was 
performed using magnetic bead isolation using the B cell isolation kit II and CD27 
microbeads to isolate memory B cells. 
 
Infection of cells 
Infection of memory B cells with EBV was performed as described earlier with minor 
modifications. Briefly, 10% (v/v) of high-titer EBV in TB-Sal was added to the memory B 
cells (106 cells/mL) to obtain a final volume of 100 μL. The cells were then subjected to 
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spinoculation at 4°C at 800xg for 60 minutes. After washing the cells twice with ice-cold 
PBS, cells were resuspended in fresh RPMI1640. 
 
Transformation assay 
To determine the transformation efficiency, B cell-depleted mononuclear cells were added to 
96-well plates as an autologous feeder layer at a cell density of 105 cells/well in a total 
volume of 80 μL. Isolated memory B cells from tonsils or peripheral blood were infected with 
EBV by spinoculation and added to the feeder layer at limiting dilutions from 1 to 104 cells 
resulting in a total volume of 100 μL. Half of the medium was changed every 3 days until 
transformation occurred after 4 weeks. Wells still showing proliferation and B cell counts 
above 95% were considered to be transformed. At least 96 wells were used in every replicate. 
 
EliSPOT and Elisa 
MultiScreen-HA Filter Plates with mixed cellulose ester membrane (Millipore) were prewet 
with 40 μL 35% ethanol. After washing the plate three times with MilliQ water, the plate was 
coated using either tetanus toxoid (10 μg/mL) or the measles virus B cell epitope peptide (100 
μg/mL) in carbonate buffer pH 9.6 for 16 hours at 4°C. After washing the plates 4 times with 
PBS, they were blocked for 1 hour at 37°C using 3% BSA fraction V in PBS. Mononuclear 
cells, isolated 6-8 days post vaccination or EBV-transformed LCL were added to the plate at 
various concentrations between 102 and 106 cells/well in RPMI1640 and the plates were 
incubated at 37°C and 5% CO2 for 6 hours. After washing away all cells first using 3% BSA 
fraction V in PBS + 0.05% Tween 20 followed by three consecutive washing steps with 3% 
BSA fraction V in PBS, horseradish-peroxidase (HRP)-conjugated mouse anti-human IgG 
(Fc) (ABD Serotec) was added to the plates at a dilution of 1:2000 in PBS + 3% BSA fraction 
V and plates were incubated at 18°C for 1 hour. Washing of the plates to remove unbound 
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antibody was performed three times with 3% BSA fraction V in PBS followed by the 
development step using TMB substrate (Mabtech) for 20 minutes at 18°C. To stop the 
development, the plates were washed extensively with MilliQ water and allowed to dry for 16 
hours at 4°C. Spots were counted manually using a Binocular microscope. 
Elisa detecting TT- or measles virus-specific IgG were performed on microtiter plates 
(Corning) using the same antigen concentration as used for EliSPOT. All washing steps are 
equal to the EliSPOT protocol. Coating was performed in carbonate buffer pH 9.6 at 4°C for 
16 hours. Blocking was performed for 1 hour at 18°C using 3% BSA fraction V in PBS 
followed by incubation with HRP-conjugated anti-human IgG (Fc) and development with 
TMB substrate. A standard curve using anti-TT antibody or anti-measles serum was also 
included. 
 
Inhibition of EBV infection 
Inhibition of EBV entry receptors on memory B cells was performed by incubating isolated 
memory B cells with either anti-human CD21 (1:10), anti-human HLA-DR,DP,DQ (1:10) or 
various dilutions of anti-β1 integrin for one hour at 4°C followed by spinoculation of the cells. 
Inhibition of EBV glycoproteins was performed by incubation of the EBV-containing 
supernatants with either anti-gp350/220 (1:10), various dilutions of anti-gp42 or soluble 
recombinant β1 integrin for 1 hour at 4°C prior to spinoculation of memory B cells.  
Inhibition of the downstream integrin signaling was performed by incubating the isolated 
memory B cells with either PP2 (10 μM), wortmannin (10 nM), Ly-294002 (10 μM), AG-82 
(10 μM) or cytochalasin D (10 μM) for 30 minutes prior to spinoculation with EBV. 
 
Western blotting 
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After washing the cells twice with ice-cold PBS, 5 x 106 cells were resuspended in 200 μL 
modified RIPA buffer containing 1% Igepal CA-630, 0.5% Sodium deoxycholate, 0.1% 
Brij35, 10 mM β-mercaptoethanol, 10 μg/ml PMSF, 5 μg/ml aprotinin, 0.1 mg/ml 
benzamidine, 1 μg/ml pepstatin A, 1 μg/ml leupeptin, 100 mM sodium orthovanadate, 1 mM 
Sodium fluoride and 15 μl/ml Triton X-100 in PBS. Antibodies used were added at a dilution 
of 1:1000 and were detected using SuperSignal Femto Western Blot detection system 
(Thermo Scientific…..) 
 
Fluorescence microscopy 
For the detection of actin rearrangements, isolated memory B cells were serum-starved for 6 
hours before performing EBV binding reactions. At defined time-points, cells were washed 
with ice-cold PBS and were cytospun on microscopy slides. Fixation was performed for 20 
minutes in 4% paraformaldehyde prior to permeabilization using 0.1% TritonX-100. Staining 
of actin was done using FITC Phalloidin and slides were …………… 
 
Flow Cytometry and Fluorescence Activated Cell Sorting 
Flow cytometry was performed using a Cytomics FC 500 (Beckman Coulter) 
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Figure legends 
Figure 1. EBV preferentially infects CD62L+ memory B cells from NALT. 
(A) Infection frequency of memory B cells from tonsils, peripheral blood and lymph nodes. 
Results shown are EGFP+ cells gated for CD19+CD27+ memory B cells. (B) CD62L 
expression on CD19+CD27+ memory B cells from tonsils, peripheral blood and lymph nodes. 
(C) CD62L expression on memory B cells from tonsils, peripheral blood and lymph nodes 
before and 24 hours after EBV infection. (D) Infection frequency of CD62L+ and CD62L- 
memory B cells from tonsils, peripheral blood and lymph nodes. Results shown are mean ± 
SD from 4-8 replicates. 
 
Figure 2. Transformation of memory B cells by EBV is only efficient in memory B cells 
specific for respiratory antigen. 
(A) Transformation efficiency of tonsillar and peripheral blood memory B cells (TC50 
transforming concentration 50). (B, C) Frequency of tetanus toxoid-specific memory B cells 
in peripheral blood of TT-naïve or TT-immunized donors before and after EBV 
transformation measured by (B) EliSPOT and (C) Elisa. (D) Frequency of measles virus-
specific memory B cells in peripheral blood of MV-naïve, MV-immunized and MV-infected 
donors before and after EBV transformation measured by Elisa. Data shown are means ± SD 
of three biological replicates. 
 
Figure 3. Integrin β1 is preferentially expressed on memory B cells from NALT. 
(A, B) Immunofluorescence of α5β1 integrin expression on memory B cells from (A) tonsil, 
and (B) peripheral blood. (C-K) Detection of α5β1 integrin on memory B cells from different 
lymphatic tissue by flow cytometry. Data shown are numbers of α5β1 integrin-positive 
memory B cells from (C, D) tonsils, (F, G) peripheral blood and (I, J) lymph nodes. (E, H, K) 
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Relative fluorescence intensity of β1 integrin on memory B cells from different lymphatic 
tissue. Data shown are mean ± SD from 3-4 biological replicates. P values were calculated by 
using the Mann-Whitney t test. 
 
Figure 4. Integrin α5β1 is required for efficient attachment and entry of EBV on memory 
B cells 
(A) Infection susceptibility of α5β1 integrin-positive and negative tonsillar memory B cells. 
Cells were either stained for the expression of α5β1 integrin 24 hours post EBV inoculation or 
were sorted by fluorescence-activated cell sorting before infection with EBV. (B) Inhibition 
of cellular receptors required for EBV infection (CD21 and HLA class II) and α5β1 integrin 
on memory B cells from tonsils using different concentrations of blocking antibodies and 
combinations. (C) Inhibition of the viral glycoproteins gp350/220 and gp42 in combination 
with competition inhibition of recombinant soluble β1 integrin using tonsillar memory B cells. 
Data shown are from one representative experiments of two replicates. 
 
Figure 5. EBV binding to integrins via BMRF2 initiates signaling cascades mandatory 
for virus entry into memory B cells. 
(A, B) Phosphorylation of FAK, c-Src, p85α, and cofilin following binding of (A) B95.8wt or 
(B) BMRF2ko EBV to isolated tonsillar memory B cells. (C) Initiation of actin filament 
reorganization triggered by binding of EBV, Fibronectin, heat-inactivated EBV or BMRF2ko 
EBV to isolated tonsillar memory B cells.  
 
Figure 6. Activation of the integrin signal transduction pathway is crucial for EBV entry 
into memory B cells 
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(A, B) Inhibition of signaling molecules c-Src, PI3 kinase, FAK, activated downstream of 
integrin impact the susceptibility of tonsillar memory B cells to EBV infection. Cytochalasin 
D was included to show the dependence of infection susceptibility of memory B cells on actin 
cytoskeletton depolymerization. 
 
Figure 7. Proposed model for the attachment and entry of EBV into memory B cells. 
EBV binding to CD21 on the cell surface triggers receptor-mediated endocytosis and, at the 
same time initiates integrin signal transduction pathways. While EBV triggers membrane 
fusion with the endosomal membrane via interaction of the viral glycoprotein complex 
gH/gL/gp42 and host cellular HLA-DR,DP,DQ, the activated integrin signaling cascade leads 
to subsequent activation of actin filament rearrangement and microtubule formation thereby 
enhancing transport of the viral capsid to the nucleus. 
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Abstract 
The γ-herpesvirus Epstein-Barr (EBV) preferentially infects human B and epithelial 
cells and is associated with a pathogenic role in neoplasia of both types. While EBV infection 
of B cells is well-characterized, mechanisms of entry into epithelial cells are poorly 
understood. Binding of the EBV glycoprotein BMRF-2 to integrins of the β1 family plays a 
crucial role in the epithelial cell infection process. Nevertheless, the mechanisms by which 
integrins facilitate EBV entry are not defined. We investigated the events triggered by EBV 
binding to epithelial cells in a tissue culture system using the model cell line AGS. We 
demonstrate that binding of EBV to integrin and subsequent intracellular signalling are crucial 
for augmenting EBV infection and that EBV triggers signalling events leading to activation of 
focal adhesion kinase (FAK). FAK and its downstream effectors PI3K and c-Src were 
essential for enhancing EBV infection as well as for EBV-mediated changes in the 
cytoskeleton. EBV binding induced activation of the regulatory small GTPase RhoA leading 
to a disassembly of cortical actin and the formation of actin stress fibres; furthermore, EBV 
caused a reorganization and stabilization of microtubuli. These data suggest pathways that 
may facilitate EBV entry into epithelial cells and further define the EBV-host interaction. A 
deeper understanding of such mechanisms is key for understanding EBV biology and notably 
pathogenesis of EBV-associated diseases.  
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Introduction 
The γ-herpes virus Epstein-Barr (EBV) is a dual cell-tropic virus that infects B cells 
and nasopharyngeal and gastric epithelial cells where it can establish latency (reviewed in 
Faulkner et al. 2000). Latent EBV has been attributed a pathogenic role in several types of 
neoplasia including B cell lymphomas in immunocompromised patients (reviewed in Young 
and Rickinson 2004). salivary gland carcinomas, gastric adenocarcinomas, and 
nasopharyngeal carcinoma (NPC) (Raab-Traub 2002). In all of these tumors, each cell is 
infected with EBV. 
 In vitro models for EBV infection have led to a detailed characterization of the 
virus entry process in B cells (reviewed in Hutt-Fletcher 2007). Here, infection is initiated by 
attachment of EBV through binding of the viral envelope glycoprotein (env gp) gp350/220 to 
its cell surface receptor CD21 (also known as complement receptor type 2 (CR2)) (Nemerow 
et al. 1989) and subsequent endocytosis of the ligand-receptor complex (Tanner et al. 1987). 
The initial interaction tethers EBV and promotes the subsequent binding of a second 
glycoprotein, gp42, which is found in a trimeric complex with the glycoproteins gH and gL, 
to HLA class II (Fingeroth et al. 1984; Tanner et al. 1987). gp42 binding to HLA class II 
induces a conformational change in the trimeric protein complex, which triggers the fusion 
machinery into an active state (Li et al. 1995). Fusion of EBV with B cells is mediated by the 
gH/gL complex and an additional protein, gB (McShane and Longnecker 2004). 
 EBV infection of epithelial cells is quite different from infection of B cells and 
remains mostly enigmatic. Epithelial cells do neither express CD21 nor HLA class II. Hence, 
binding of env gp350 and gp42 is not possible. While a trimeric complex of gH/gL and gp42 
is needed for infection of B cells, addition of soluble gp42 to a dimeric gH/gL complex has an 
inhibitory effect on EBV’s fusion with epithelial cells (Wang et al. 1998). To enable dual cell 
tropism, the virus thus carries both dimeric and trimeric complexes, the ratio of which 
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depends on the cellular origin of the virus (Borza and Hutt-Fletcher 2002). The minimal viral 
requirement for EBV fusion with epithelial cells is the expression of the glycoproteins gH, gL 
and gB. Though, close cell–cell contact and the expression of the glycoproteins are not 
sufficient, hinting at the need for a receptor or attachment factor on the target cell itself 
(McShane and Longnecker 2004). The finding that binding to epithelial cells can be blocked 
by antibodies to gH/gL suggests a critical role of this glycoprotein complex in receptor 
binding. Taking into account the inhibitory effect of soluble gp42, the cell domain which 
interacts with gp42 in the trimeric complex most likely exhibits important binding receptor 
function (Kirschner et al. 2006). Thus, while the core fusion function of gH/gL remains 
identical for B cells and epithelial cells, the way in which it is triggered into a functionally 
active state by binding receptors differs considerably (Wu et al. 2005). 
In addition to the putative gH/gL receptor, other cellular factors might be involved in 
EBV binding to epithelial cells. A recently identified EBV env glycoprotein, BMRF-2, has 
the ability to bind to integrins of the β1 family through its RGD (Arg-Gly-Asp) motif (Xiao et 
al. 2008). An inhibition of this interaction substantially decreases infection, implicating a 
crucial role for integrins in EBV binding (Tugizov et al. 2003). BMRF-2 is expressed at the 
basolateral membranes of EBV-infected epithelial cells and may thus also play a role in the 
direct cell to cell spread of EBV in epithelia (Xiao et al. 2007). Nevertheless, the mechanisms 
by which the BMRF-2-integrin interaction facilitates EBV entry and infection are not defined. 
Integrins are a family of heterodimeric receptors composed of non-covalently linked 
class I transmembrane α and β subunits (Giancotti 1999). In man at least 24 different receptor 
combinations are found that can be grouped into three sub-classes according to their ligand-
specificity, one of which is defined through its RGD-binding properties, and interacts with 
extracellular matrix (ECM) components like Fibronectin and Vitronectin (reviewed in 
Wiesner 2005). The most basic property of integrins is to provide a mechanically strong 
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connection between cells and the ECM. This connection mediates a wide array of functions 
such as activation of endocytosis, attachment, motility, regulation of gene expression, cell 
survival, cell cycle progression, apoptosis, differentiation and regulation of the cytoskeleton 
(Giancotti 1999). When active integrins bind to their ECM ligands, their cytoplasmic tails 
recruit proteins that trigger the assembly of micrometer-sized structures termed cell matrix 
adhesion complexes (MACs), which can be further differentiated into focal adhesions (FA). 
FAs are built up by integrins and numerous signalling molecules, such as focal adhesion 
kinase (FAK), Src kinases, phosphoinositol-3-kinases (PI3Ks) and cytoskeletal proteins like 
talin, paxillin, vinculin and α-actinin. FAs thus link the ECM proteins on the outside of the 
cell with the cytoplasmic actin cytoskeleton on the inside (Clark and Brugge 1995; Parsons 
1996; Giancotti 1999; Wiesner 2006). The signalling cascades within FA eventually lead to 
the recruitment and activation of Rho GTPases and their effectors, which in turn regulate the 
activity of actin nucleation factors (Ridley 2001), such as the Arp2/3 complex and the 
forming protein family (Pollard 2003; Higgs 2005).  
 It has been shown for several viruses that binding to the plasma membrane and in 
particular to integrins triggers intracellular signalling events preparing the cell for invasion. 
These signalling events may activate endocytosis leading to the uptake of the virus as in the 
case of adenovirus 2 (Meier et al. 2002), or simply facilitate fusion with the plasma 
membrane (Cheshenko et al. 2003). In the case of herpes viruses, several examples of 
integrin-mediated signalling exist. Human cytomegalovirus (HCMV) uses αvβ3 integrins as 
co-receptors and triggers signalling leading to RhoA down regulation, actin disassembly and 
facilitated capsid transport to the nucleus (Wang et al. 2005). Karposi’s sarcoma-associated 
herpesvirus (KSHV) induces an integrin-dependent focal adhesion kinase-Src signalling 
pathway, leading to activation of Rho GTPases and changes in the cytoskeleton, which 
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include increased formation of microtubules serving also in this case for capsid transport to 
the nucleus (Sharma-Walia et al. 2004; Naranatt et al. 2005; Raghu et al. 2007).  
 This study was undertaken to investigate whether EBV binding to integrins 
also triggers signalling processes, which facilitate infection with the virus in any way. We 
used  virus binding to and infection of the epithelial gastric adeno-associated carcinoma cell 
line (AGS) as a model to study EBV infection of epithelial cells and could show several lines 
of evidence that not only binding to but also integrin signalling is essential. We further 
demonstrated that EBV interaction with integrins leads to activation of focal adhesion kinase 
and down-stream effectors, which culminates in RhoA activation and changes of the 
cytoskeleton that may facilitate virus entry. 
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Materials and Methods 
Cells and culture. The EBV-infected marmoset cell line B95.8 EBfaV-GFP was 
maintained in RPMI 1640 medium (Gibco, Basel, Switzerland) supplemented with 10% heat-
inactivated fetal bovine serum and 1% penicillin-streptomycin, referred to hereafter as 
complete RPMI. The human adeno-associated gastric carcinoma cell line AGS (ATCC CRL-
1739) was maintained in Ham’s F-12 medium (Gibco) supplemented with 10% fetal bovine 
serum, 1% penicillin-streptomycin and 1% L-glutamine, referred to hereafter as complete 
Ham’s F-12, and split twice a week. 
Preparation of EBV stock. B95.8 EBfaV-GFP cells were seeded at a density of 106 
cells/ml and were stimulated to release virus by culture for 4 days in complete RPMI 
containing 50 ng/ml of 12-O-tetradecanoylphorbol-13-acetate (TPA; Sigma-Aldrich, Buchs, 
Switzerland). Cell suspensions were centrifuged at 400 x g for 5 min. Supernatants were 
passed through a 45-μm-pore-size cellulose acetate filter (Millipore, Zug, Switzerland) and 
stored at -80°C. For purification and concentration the supernatants were centrifuged for 4h at 
4°C and 17000 rpm to pellet the virus. The supernatants were poured of and virus pellets 
resuspended in TBSal (200 mM NaCl, 2.6 mM KCl, 10 mM Tris-HCl pH 7.5, 20 mM MgCl2, 
1.8 mM CaCl2)) and frozen in aliquots at -80°C. The virus was titrated on primary B cells 
isolated from tonsilar mononuclear cells (see ref Dorner for details) to determine infectivity. 
Plasmids. The plasmids pCMVIL2R encoding the full-length tac subunit (CD25) of 
the IL2-receptor and pCMVIL2Rβ1 encoding the extracellular and transmembrane domains of 
the tac subunit of IL-2 receptor connected to the wild-type β1 integrin cytoplasmic domain 
acting as dominant negative have been described before (LaFlamme 1994 JCB) and were 
obtained from Susan LaFlamme (Albany Medical College, Albany, NY, USA).  
Antibodies and reagents. Monoclonal antibodies directed against focal adhesion 
kinase and phosphorylated focal adhesion kinase (Y397) were purchased from BD 
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Biosciences (Basel, Switzerland). Monoclonal antibodies against tubulin (B-5-1-2) and 
acetylated tubulin (6-B11-1) were from Sigma-Aldrich. Polyclonal rabbit antibody against β-
actin was from BioConcept (Allschwil, Switzerland). CD25 MicroBeads and mouse anti-
CD25-PE antibodies for MACS sorting and subsequent FACS analysis were purchased from 
Miltenyi Biotech (Bergisch-Gladbach, Germany). The monoclonal antibody directed against 
RhoA was part of the Rho Activation Assay Biochem Kit from Cytoskeleton (Denver, CO, 
USA). Alexa-Fluor coupled secondary anti-mouse and anti-rabbit reagents were from 
Invitrogen (Basel, Switzerland) and HRP-coupled secondary anti-mouse and anti-rabbit 
reagents from Pierce Biotechnology (Rockford, USA). The soluble recombinant β1 integrins 
(CD29) were synthesized at RayBiotech (Norcross, USA). FITC-coupled Phalloidin, 
Fibronectin, the PI3K inhibitors Ly294002 and Wortmannin as well as the actin 
depolymerising agent Cytochalasin D were all purchased from Sigma-Aldrich. The tyrosine-
kinase inhibitor AG82 (Tyrphostin A25) and the c-Src inhibitor PP2 were both from 
Calbiochem (ordered at Merck, Nottingham, UK). 
 Transfection and cell sorting. AGS cells were transfected using the Nucleofector 2 
from Amaxa Biosystems (Cologne, Germany) according to the manufacturer’s protocol. In 
brief, the cells were trypsinized and washed in PBS and pelleted at 1,500 rpm/5min. 106 cells 
were resuspended in 100 μl buffer V (Amaxa) and mixed with 2 μg plasmid DNA. The cells 
were pulsed with programme B-023, taken up in warm complete Ham’s F-12 and plated for 
experiments or subsequent sorting. Transfected cells were processed for positive MACS 
sorting with CD25 Microbeads II from Miltenyi according to the manufacturer’s protocol 
after 24 h. The purity of sorted populations was checked by flow-cytometry using compatible 
anti-CD25-PE from the same company. Typically, sorting of a population with 30% 
expressing cells yielded a purity of 70-80%. 
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EBV infection and binding. To determine infection efficiencies after treatment of 
cells with inhibitors at 37°C for 30 min or 1h as specified, high-speed centrifugation purified 
virus from TPA induced B95.8EBfaV-GFP cells was used to infect AGS cells by 
spinoculation. In detail, 50 μl of concentrated virus was added to 3 x 105 AGS cells in 6-well 
plates with 500 μl complete Ham’s F-12 and the cells were centrifuged for 1 h at 800 x g at 
room temperature in presence of the inhibitor where required. After spinoculation, cells were 
washed in phosphate-buffered saline (PBS) and supplied with fresh complete medium. Two 
days later, the infection of cells was assessed by flow cytometry quantifying the expression of 
GFP. To assess the activation of signalling pathways and changes in the cytoskeleton by 
Western blot and immunofluorescence methods AGS cells were serum-starved for 24h at 
37°C. 50 μl purified virus was added to the cells in 500 μl serum-free Ham’s F-12 and 
incubated at 37°C for 5 to 60 min as indicated. Cells were put on ice, washed in phosphate 
buffered saline and processed for subsequent assays. 
Flow cytometry. Flow cytometry was carried out on a Cytomics FC500 instrument 
(Beckman Coulter, Nyon, Switzerland) with FlowJo software, used in accordance with the 
instructions of the manufacturer (Treestar, Ashland, USA). 
Immunofluorescence. AGS cells grown on glass coverslips in 24-well plates were 
fixed in 4% paraformaldehyde in phosphate-buffered saline for 20 min. the fixation was 
stopped by two washes in Hepes-buffered serum-free Ham’s F-12 and subsequent incubation 
at 4°C in phosphate-buffered saline (PBS) containing 1 mM CaCl2 and 0.5 mM MgCl2. Cells 
were permeabilized with a buffer containing 0.05% Saponin, 10% fetal bovine serum, 15 mM 
Glycin, and 10 mM Hepes in PBS for 15 min and subsequently stained in the same buffer 
with added antibodies or Phalloidin. Each antibody incubation step was followed by five 
washes in permeabilization buffer, the last one additionally by two washes in PBS. The 
coverslips were briefly rinsed in deionised water and mounted onto glass slides in ProLong 
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Gold Antifade reagent containing DAPI (Invitrogen). Samples were analyzed by 
epifluorescence with a Zeiss Axioskope 2 and AxioVision 4.4 software (Carl Zeiss Vision 
GmbH, Feldbach, Switzerland). Images were assembled with Adobe Photoshop 6.0. 
Western blotting. Cells were lysed on ice in RIPA buffer (50 mM Tris-HCl, 150 mM 
NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulphate, 0.5% sodium deoxy cholate) 
supplemented with complete mini protease inhibitor cocktail (Roche Applied Sciences, 
Rotkreuz, Switzerland), sodium fluoride and 1 mM sodium orthovanadate (Sigma-Aldrich) 
for 15 min. Cell debris and nuclei were removed by centrifugation at 12,000 rpm/10 min/4°C 
and proteins resolved by 10% SDS PAGE before transfer to nitrocellulose membranes. 
Antibody incubations were generally done in PBS with 0.1% Tween and 5% fat free dried 
milk. For the detection of primary antibodies horseradish peroxidase-labelled goat anti-mouse 
or anti-rabbit reagents from Pierce were used. Signal detection was performed by using the 
enhanced-chemiluminescence substrate from Pierce and scanning directly with the 
ChemiGenius imaging system (SynGene, Cambridge, UK). Signals were quantified with the 
GeneTools 3.1 image analysis software (SynGene). 
RhoA pull-down assay. Quantification of RhoA-GTP was performed using the Rho 
Activation Assay Biochem Kit from Cytoskeleton (Denver, USA) according to the 
manufacturer’s instructions. In brief, cells treated with EBV were lysed on ice in the provided 
buffer and debris removed by centrifugation. All samples were snap-frozen in liquid nitrogen 
straight after lysis to prevent GTP hydrolyis. Protein concentrations were equalized and 800 
μg of total lysate used for pull-down with 15 μg of rhotekin-sepharose beads. Eluates from 
the pull-down were subsequently analyzed by SDS-PAGE and Western blotting for RhoA in 
comparison to total lysate. For positive and negative pull-down controls, lysates were loaded 
with GDP or the non-hydrolysable GTPγS prior to addition of beads. 
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Results 
EBV infection of epithelial cells is augmented by binding to integrin and integrin 
signalling. 
EBV can enter tongue and pharyngeal epithelial cells through three different 
CD21/independent pathways, either by cell-to-cell spread directly across lateral membranes, 
by transfer from infected B cells to apical membranes or as cell-free virion by direct infection 
through basolateral membranes (Tugizov et al. 2003). Infection with cell-free virions is, at 
least in part, mediated by a direct interaction of the viral glycoprotein BMRF-2 with integrins 
of the β1-family, which facilitates binding of the virus to the cell (Tugizov et al. 2003; Xiao et 
al. 2008). Nevertheless, it has not been demonstrated, whether integrins only serve a binding 
role or whether EBV is triggering integrin-mediated signalling facilitating it’s own entry. To 
show that EBV binding to integrins is indeed crucial for augmenting infection, we pre-treated 
purified B95.8 EBfaV-GFP virions with increasing concentrations of soluble recombinant β1 
integrins to block the binding sites on BMRF-2. The pre-treated EBV was subsequently used 
to infect the epithelial model cell line AGS by spinoculation. The number of infected cells 
was assessed by flow cytometry detecting the amount of GFP expression after 48h. EBV 
treatment with soluble integrin significantly reduced infection in a concentration-dependent 
manner (Fig. 1A) indicating a need for integrin binding on the host cell. We thus wanted to 
investigate the implications of integrin signalling on infection efficiency using dominant 
negative constructs: fusion proteins joining the β1 integrin cytoplasmic domain to the 
transmembrane and extracellular parts of the interleukin 2 receptor α-subunit (IL2R) have 
been described previously (LaFlamme 1994; Bodeau AL 2001), and are inhibiting 
endogenous integrin signalling by binding to down-stream effector proteins. We used 
plasmids encoding the dominant negative (DN IL2Rβ1) or the full-length interleukin 2 
receptor α-subunit (IL2R, as a control) to nucleofect AGS cells and obtained approximately 
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30% of expressing cells as determined by flow-cytometry and IL2R staining (data not shown). 
To enrich the expressing population we sorted the nucleofected cells using MACS-beads 
coupled to antibodies recognizing the extracelullar part of the IL2R, what yielded 70-80% 
purity. The selected cells were subsequently spinoculated with EBV (B95.8 EBfaV-GFP) and 
the infection analyzed by flow cytometry of GFP expression compared to untransfected cells 
(Fig. 1B). While infection remained unchanged in cells expressing the IL2R control, it was 
reduced to below 50% of controls in cells expressing the dominant negative construct, 
indicating that integrin signalling essentially contributes to augment infection.  
EBV triggers the activation of focal adhesion kinase. 
The non–receptor protein tyrosine kinase focal adhesion kinase (FAK) plays a central 
role in signalling through integrins and a variety of other receptors (reviewed in Parsons 
2003). It links signals from the extracellular matrix (ECM) to PI3kinases, Src kinases and 
regulatory elements of the cytoskeleton, and its activation leads to autophosphorylation of 
Y397 (reviewed in Wiesner 2005). To test whether EBV binding to integrins on AGS cells 
leads to activation of FAK, we incubated cells for varying times with EBV or the ECM 
integrin ligand Fibronectin as a positive control at 37°C, and analyzed them by 
immunofluorescence staining with an antibody specific for FAK phosphorylated at Y397. 
Distinct spots of staining were observed after 1h Fibronectin treatment (Fig. 2A second panel 
from left), which were not visible in control cells. Treatment of cells with EBV for 15 min led 
to a weak signal for phosphorylated FAK at the plasma membrane that grew substantially 
stronger after incubation with EBV for 60 min and was distributed evenly along the plasma 
membrane of the cells, indicative of accumulative activation. To quantify FAK activation, 
cells treated with either Fibronectin or EBV were lysed and processed for Western blotting 
with the phophorylated Y397 FAK specific antibody. Staining of the same blots for β-actin 
was used as a loading control. Quantification of a representative experiment out of several 
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(Fig. 2B), showed an approximately four-fold activation of FAK after Fibronectin treatment. 
In agreement with the immunofluorescence experiment, a weak activation (1.3 fold) was 
observed after 15min EBV treatment, which grew stronger (2 fold) after 60 min. We 
concluded that EBV binding to AGS cells triggers activation of FAK.  
 To address a role for FAK in EBV epithelial cell infection, the protein tyrosine 
kinase inhibitor AG82 was used, which has been shown to inhibit FAK activity in some cell 
types (Tsuda et al. 1997). AGS cells were incubated for 30 min with increasing concentrations 
of AG82 and subsequently spinoculated with EBV in presence of the inhibitor. Infection 
efficiency was determined by flow-cytometry after 2 days. While 5μM of AG82 did not affect 
EBV infection, a reduction to around 60% of controls was observed at 10 μM and 25 μM, 
respectively (Fig. 2C). Higher concentrations showed a weaker effect, probably due to non-
specific inhibition of phospho-tyrosine kinases with contrasting functions, and concentrations 
above 50 μM were toxic for the cells (not shown).  
 EBV infection is dependent of signalling pathways downstream of FAK. 
Phosphorylation of FAK creates a binding site for Src and enables interactions with 
the SH2 domain of phosphoinositide 3-kinase (PI3K), activating down-stream signalling 
pathways (reviewed in Wiesner 2005). We thus wanted to investigate whether these pathways 
are essential for augmenting EBV infection. The function of PI3K is irreversibly inhibited by 
Wortmannin, which interferes with its catalytic subunit, and reversibly by Ly294002 (Araki et 
al. 1996), while function of c-Src family kinases can be blocked with 4-Amino-5-(4-
chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). We pre-treated AGS cells with 
above three inhibitors for 1 h and subjected them to spinoculation with EBV in presence of 
the inhibitors. The cells were then incubated at 37°C until infection became visible by GFP 
expression after 2 days. We observed a clear infection decrease after treatment with 
Ly294002 (less than 5% of control) or Wortmannin (40% of control) (Fig. 3) indicating that 
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signalling processes requiring PI3K are essential. Blocking the key modulator kinases of the 
c-Src family with PP2 also led to a reduction of infection to approximately 40% of control 
(Fig. 3), suggesting a need for c-Src signalling for augmenting infection.  
 EBV triggers a reorganization of the actin cytoskeleton facilitating 
infection. 
Among the hallmarks of integrin interaction with ligands are reorganization and 
remodelling of the actin cytoskeleton, which are controlled by small GTPases of the Rho 
family such as RhoA, Rac and Cdc42. RhoA mediates the formation of stress fibers, 
elongated actin bundles traversing the cell and promoting cell attachment to the ECM (Tapon 
1997), while Rac and Cdc42 are responsible for the formation of lamellipodia or ruffles and 
filopodia, respectively. These GTPases can be activated upon FAK and Src induction via 
PI3Ks and have effects on FA assembly through actin filament reorganization. Activation of 
FAK by EBV binding, as well as the above suggested involvement of PI3K and c-Src 
signalling in EBV infection, prompted us to investigate, whether the EBV induced signalling 
cascades could also mediate cytoskeletal reorganization.  
 AGS cells were serum-starved for 24h and subsequently treated with serum-
free Ham’s F12 (controls) or with serum-free Ham’s supplemented with 40μg/ml Fibronectin 
or EBV for 15 min or 60 min at 37°C. The cells were subsequently fixed, permeabilized and 
stained with FITC-coupled Phalloidin for analysis by epifluorescence. Serum-starved control 
cells exhibited strong peripheral F-actin staining along the cell edges, indicative of cortical 
actin fibres. The margins of the cells were well defined and smooth (Fig. 4A top left panel). 
Treatment of cells with Fibronectin induced the polymerization of actin, visible as stress 
fibres inside the cell, while part of the strong cortical actin was still present (Fig. 4A, top right 
panel). 15 min of incubation with EBV led to a much more pronounced stress fibre pattern, 
stretching throughout the whole cells. At this point the cortical actin had completely 
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disappeared and the edges of the cells appeared less even (Fig.4A bottom left panel), 
indicative of substantial actin reorganization. After 60 min of incubation with the virus the 
stress fibres were still visible, but part of the cortical actin staining had reappeared, what 
suggested a decrease of the EBV-induced signal and return to the original state of the cells 
(Fig.4A, bottom right panel). We thus concluded that EBV binding induced changes in the 
actin cytoskeleton, which resulted in a shift from a predominant cortical form to intracellular 
stress fibres. 
 We next wanted to investigate whether the demonstrated changes in the actin 
cytoskeleton are indeed mediated by in above experiments suggested FAK, PI3K and c-Src 
involving pathways. To this end we incubated serum starved AGS cells with non-toxic 
concentrations of the corresponding inhibitors of the kinases, AG82, Ly294002 and PP2 
respectively, before triggering actin reorganization with EBV. Actin staining in control cells 
showed that the inhibitors did not markedly change the morphology of the cells (Fig. 4B top 
row). While some cells showed a slightly more rounded shape and retracted from the 
coverslips, most remained attached and exhibited a strong cortical actin pattern reminiscent of 
the untreated control cells in Fig 4A. In contrast, EBV incubation did not lead to pronounced 
stress fibre formation as observed in cells without inhibitors earlier. After 15 min the cortical 
actin was still partly present, particularly in AG82 or PP2 treated cells, and fibres had only 
formed around the edges of the cells to a very small extent. This state persisted even after 60 
min of EBV treatment (Fig. 4B lower panels). We thus concluded that AG82, Ly294002, or 
PP2 efficiently inhibited EBV-mediated stress fibre formation and that thus the trigger may be 
transmitted by pathways including FAK,  PI3K, and c-Src. 
 We subsequently wanted to analyze, whether the disruption of actin fibres with 
non-toxic doses of Cytochalasin D affected EBV infection. AGS cells were thus treated with 
Cytochalasin D for 1h prior to EBV infection by spinoculation in the presence of the 
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disrupting agent. We surprisingly observed that infection efficiency was increased by almost 
4-fold after treatment compared to mock (solvent only) treated cells (Fig. 4C). This result led 
to the speculation that not the formation of stress fibres, but rather the disassembly of the 
cortical actin was required for the infection process. 
 EBV triggers activation of RhoA 
Considering the substantial changes in the actin cytoskeleton by EBV binding to AGS 
cells, we wanted to investigate, whether EBV had a direct influence on the activation status of 
the actin stress fibre regulating small GTPase RhoA. AGS cells serum starved for 24h were 
thus treated with either medium control or EBV for times ranging from 5 min to 60 min and 
subsequently washed and directly lysed. The amount of total protein in the samples was 
equalized and a total lysate probe of each sample analyzed by Western blotting for the 
expression of total RhoA (Fig. 5A, lower panel). Equal amounts of lysates from each sample 
were subjected to a pull-down assay with sepharose beads coupled to the RhoA effector 
protein rhotekin, which specifically binds to only the GTP-bound, activated form. As positive 
and negative controls for the pull-down assay, we used lysates of the control sample, which 
was preloaded with either the non-hydrolysable GTPγS (positive control) or GDP (negative 
control). The eluate fractions from the pull-down were separated by SDS-PAGE and 
subsequently analyzed by Western blotting with a RhoA specific antibody. The RhoA 
detected in this case should be exclusively in the GTP-bound form (Fig. 5A, top panel). Band 
intensities were strongest for the positive control, as expected, and increasing with the time of 
EBV treatment. The intensities of the scanned bands were quantified and the mock sample set 
to a one-fold activation. RhoA-GTP levels in the mock sample corresponded to the GDP 
loaded negative control, while a max. 2.5-fold increase was observed after loading with non-
hydrolysable GTP. In the EBV treated samples we observed a step-wise increase with time of 
treatment, where max levels of approx. 2.4-fold activation were reached after 60 min (Fig. 
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5B). These results indicated that EBV treatment of AGS cells could indeed trigger activation 
of RhoA, which results in the previously demonstrated EBV-mediated reorganization of the 
actin cytoskeleton. 
 EBV modulates the microtubuli network and increases tubulin 
acetylation. 
By binding to integrin and the subsequent activation of FAK, KSHV leads to 
rearrangements in the actin cytoskeleton as well as changes in the microtubuli (MT) network, 
which are facilitating virus entry into the host cell (Sharma-Walia et al. 2004; Naranatt et al. 
2005; Raghu et al. 2007). We, therefore, wanted to investigate whether the same was the case 
for EBV. AGS cells serum-starved for 24h were thus exposed to EBV for either 15 min or 60 
min, fixed, permeabilized and reacted with a mouse antibody to α-tubulin (Fig. 6A left 
panels) or a mouse antibody recognizing actetylated tubulin (Fig. 6A right panels), which is a 
quantitative indication of changes in MT stabilization (Piperno 1987). Control cells showed a 
tight meshwork of microtubuli, which was concomitant with evenly distributed low 
acetylation levels. The microtubuli in the control cells did not have any particular direction or 
ordering. After 15 min or EBV treatment, the tubuli network appeared less dense, especially 
around the edges of the cells. The acetylation pattern was substantially stronger around the 
nucleus and appeared on a filamentous tubuli structure stretching from the nucleus to the 
edges of the cell. The pattern grew more pronounced after 60 min of EBV exposure, when 
tubuli appeared as ordered, stretched hair-like structures pointing to the cell edges that had 
become uneven and pointed in several places. At this point the acetylation was almost 
exclusively visible around the nucleus. 
To further analyze the influence of EBV on MT dynamics we quantified the levels of 
tubuli acetylation by Western blotting (Fig. 6B). While mock treated cells contained moderate 
levels of acetylated tubulin, these levels first decreased upon EBV addition and then steadily 
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increased over time for the first 30 min to decrease after 60 min (Fig. 6B upper panel). The 
levels of total α-tubulin remained unchanged, thus demonstrating the specificity of tubulin 
acetylation (Fig. 6B, lower panel). Quantification of the Western blot bands, where levels of 
mock treated cells were set to one-fold acetylation, showed that after a first drop to around 
0.5-fold, acetylation levels increased to 1.7-fold after 30 min and decreased at later time 
points (Fig. 6C). These results indicated that EBV binding first led to a destabilisation of 
microtubuli, which resulted in a reorganization and stabilisation later during EBV entry. 
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Discussion 
This is the first study to investigate EBV-mediated intracellular signalling processes 
associated with EBV entry into epithelial cells.  
Based on the recent finding of EBV binding to integrins and their crucial role in 
infection (Tugizov et al. 2003), we assessed the significance of integrin signalling for EBV 
entry and analyzed virus triggered processes inside the host cell using a tissue culture system 
with the gastric epithelial model cell line AGS. The CD21-negative AGS cells had previously 
been evaluated to be susceptible to EBV (Imai et al. 1998), and we managed to substantially 
improve the efficiency of cell-free infection using a spinoculation-based method originally 
developed for the EBV infection of B cells (Dorner et al. 2008).  
Our data showed that, apart from serving as an attachment factor binding to EBV 
BMRF-2 (Tugizov et al. 2003; Xiao et al. 2007; Xiao et al. 2008), β1 integrins transmitted 
signals that were crucial for augmenting EBV infection. These signals were most likely 
triggered by EBV itself and led to FAK activation by autophosphorylation at Y397. We 
further demonstrated that downstream signalling involving PI3K and c-Src was essential for 
infection and required for the EBV-induced formation of actin stress fibres and degradation of 
cortical actin in the epithelial cell. The stress fibre formation was most likely regulated by a 
proven EBV-dependent activation of the small GTPase RhoA. In addition, we also discovered 
a rearrangement of microtubuli upon virus binding to cells, which was reflected by a transient 
change in the stabilization state (summarized in Figure 7). Binding to integrins is a proven 
concept in the world of herpes viruses, and signalling leads to manifold effects facilitating 
virus entry, ranging from the disassembly of actin stress fibres enabling faster nuclear 
trafficking of capsids for HCMV (Wang et al. 2005) to  the modulation of microtubule 
dynamics for DNA delivery of KSHV (Sharma-Walia et al. 2004; Naranatt et al. 2005). Our 
observations with EBV thus fit the picture; integrins and downstream signalling led to 
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cytoskeletal changes that were clearly linked with the efficiency of infection. Apart from the 
inhibition of EBV infection, we noticed that expression of dominant negative integrins 
disabling downstream signalling led to morphological changes in the cells that stood in sheer 
contrast to the changes triggered by EBV: Whilst EBV led to spreading of cells, the dominant 
negative expressing cells were rounded and unable to form protrusions (data not shown). This 
finding once again underlines the need for spreading and stress fibre formation for infection 
and clearly links it to integrins.  
FAK activation is one of the key events that follow immediately after integrin-ligand 
interaction (Akula et al. 2002). We now report EBV mediated FAK activation for the first 
time that is most likely linked to EBV BMRF-2 binding to integrins. Other members of the 
herpes virus family are also able to trigger FAK such as KSHV (Sharma-Walia et al. 2004) or 
HSV-1 (Cheshenko et al. 2003; Cheshenko et al. 2007): KSHV triggers FAK by binding to 
integrins, HSV-1 triggers FAK activation through binding to nectin-1 on apical cell surfaces 
and an associated calcium release in the cell (Cheshenko et al. 2003; Cheshenko et al. 2007).  
The tyrosine kinase inhibitor AG82 was able to substantially reduce EBV infection, 
indicating that FAK signalling participated in processes crucial for EBV entry. These 
processes related to the observed cytoskeletal changes induced by the virus, yet they could 
also be part of other mechanisms essential for EBV entry, since FAK stands at a signalling 
crossroads. It also has to be considered that inhibition of infection was only observed at a 
certain concentration, higher concentrations of AG82 reversed the inhibition. This could be 
due to multiple functions of FAK in EBV entry, but also to the unspecific behaviour of the 
inhibitor affecting other tyrosine kinases, which may differ at certain concentrations and 
which may have opposing functions with respect to EBV infection. The observation of FAK-
dependent entry of EBV is reminiscent of KSVH- or HSV-1-entry which is facilitated by 
virus-induced activation of FAK (Cheshenko et al. 2005; Galen et al. 2006). Downstream 
 111
Manuscripts 
signalling of FAK involves PI3Ks and c-Src family proteins (reviewed in Wiesner 2005) and 
we demonstrated that these kinases were implicated in the observed EBV-mediated changes 
in the actin cytoskeleton. Inhibition of their function severely affected EBV infection, hinting 
at a pivotal role in the EBV epithelial cell entry process. It has to be understood, however, that 
they may be playing a far bigger part than regulating the observed cytoskeletal 
rearrangements. Both kinases are vital links between integrin and other receptor-mediated 
signalling with a variety of cellular functions, including endocytosis, and their role in EBV 
entry infection will need to be examined in detail. It is also not clear in which order the 
kinases participate in EBV-triggered signalling cascades. In the case of KSHV-mediated 
cytoskeletal changes Src controls the activation of PI3K after an integrin trigger (Sharma-
Walia et al. 2004), Src and PI3K activation are regulated by two different receptors after 
HCMV binding to host cells (Wang et al. 2005) and even an uncoupling of the two pathways 
after a common trigger was demonstrated (Bouchard et al. 2007). Since more receptors or 
attachment factors for EBV glycoproteins other than BMRF-2 potentially exist on epithelial 
cells (Borza et al. 2004), a more complex triggering of signalling cascades will have to be 
investigated once these receptors have been identified. 
Viruses have evolved a variety of interactions with host cells to facilitate their entry by 
inducing changes in the cytoskeleton. While modulation of actin can lead to activation of 
endocytosis pathways or facilitate virus fusion at the plasma membrane (reviewed in Favoreel 
et al. 2007), capsids of particularly herpes viruses use microtubule-based transport to reach 
the nucleus and deliver their DNA (reviewed in Smith and Enquist 2002; Dohner et al. 2005). 
Here we demonstrate both, EBV initiated changes of the actin and microtubule networks. 
EBV induced a reorganisation from a predominately cortical actin cytoskeleton to pronounced 
stress fibres. This stays in contrast to the previously reported disassembly of stress fibres 
induced by other herpesviruses like HCMV (Wang et al. 2005), but was also observed for 
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KSHV (Sharma-Walia et al. 2004). It has been proposed that EBV fuses directly with the 
plasma membrane for entering epithelial cells 5.  Thus the observed disassembly of cortical 
actin may be crucial to overcome the cortical actin barrier for efficient infection. An example 
from the herpesvirus family for this mechanism is HSV-1. It probably tackles this problem by 
activation of calcium signalling pathways (Cheshenko et al. 2003), which are well known to 
induce cortical actin depolymerization (Pollard 2003). Further evidence that this may be the 
case is provided by our observation in this study that Cytochalasin D treatment substantially 
increases EBV infection despite or even because of its actin depolymerizing properties. It 
became clear, however, that EBV affects actin regulatory elements such as the small GTPase 
RhoA, which is responsible for signal transduction leading to different modulations in the 
actin network (Etienne-Manneville and Hall 2002). 
Microtubules and microfilaments have long been recognized as crucial in controlling 
the intracellular movements of viruses. Capsids of KSHV and HSV-1 surf on microtubules to 
reach the nucleus (Sodeik et al. 1997; Naranatt et al. 2005; Raghu et al. 2007) and they may 
also play a role at later stages of infection to enable directed release of newly formed virions 
(Arakawa et al. 2007). We observed that EBV triggered a change from a complex tubuli 
network to a more organized bundle of strings reaching from the nucleus to the edges of the 
cell. This directed orientation may well hint at a function in transport of EBV capsids from 
the plasma membrane to the nucleus. Taken together the here presented study reveals how 
EBV facilitates its own entry into epithelial cells by triggering signalling processes leading to 
changes in the cytoskeleton. Understanding EBV-mediated signalling may contribute to as yet 
undiscovered entry pathways of EBV into epithelial cells. EBV triggered integrin signalling 
may add to the pathogenesis of EBV-associated epithelial cancer and eventually provide us 
with new approaches to interfere with EBV infection and thus lead to novel ways of 
prevention and treatment of EBV-associated epithelial cell neoplasia. 
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Figure Legends 
Fig. 1. EBV infection is dependent on β1integrin binding and signalling function. (A) 
High-speed centrifugation-purified TPA-induced EBV (B95.8 EBfaV-GFP) was incubated 
with 0, 2 or 5 μg/ml recombinant soluble β1integrin for 1h on ice. The treated EBV was 
subsequently used to infect AGS cells by spinoculation at 37°C. AGS cells were incubated for 
48 h before the infection efficiency was analyzed by measuring GFP expression by flow 
cytometry. (B) AGS cells were nucleofected with plasmids encoding the DN IL2Rβ1integrin 
and the IL2R control or left untransfected. Nucleofected cells were incubated for 24h and 
positively sorted for expression of the IL2R epitope with MACS beads coupled to anti-IL2R. 
Positive cells and untransfected controls were grown for an additional 24h and infected with 
EBV by spinoculation at 37°C. The efficiency of infection was determined after 48h by 
measuring GFP expression by flow cytometry. Infection efficiency was expressed as % of 
untransfected or mock controls, which were assigned a value of 100%. Each bar represents 
the mean ± SD of two (A) and three (B) experiments conducted in duplicate or triplicate 
each?, respectively.  
 
Fig. 2. EBV binding leads to activation of FAK, which is required to augment 
infection. (A) AGS cells were grown on coverslips and starved in serum-free medium (SFM) 
for 24h. The cells were left in SFM (controls), treated with 40 μg/ml Fibronectin for 1 h or 
incubated with EBV for 15 min or 60 min at 37°C. All samples were fixed in PFA, 
permeabilized and stained with mouse anti-phospho-FAK antibodies (Y397) and a secondary 
Alexa488-coupled anti-mouse reagent. Samples were mounted in anti-fade reagent containing 
DAPI and analyzed by epifluorescence. White arrow heads indicate accumulations of 
phosphorylated FAK. (B) Serum-starved AGS cells were left uninduced (control), induced 
with 40μg/ml Fibronectin for 1 h or with EBV for 15min and 1h at 37°C. Cells were cooled 
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on ice, lysed in RIPA buffer and cell debris and nuclei were removed. The supernatants were 
resolved by 10% SDS PAGE, Western blotted and reacted with mouse anti-phospho-FAK 
(Y397) and rabbit anti-β-actin antibodies as a loading control. Immunoreactive bands were 
visualized by an enhanced-chemiluminescence reaction. Band intensities for phosphorylated-
FAK were normalized according to β-actin expression and quantified. Bars show band 
intensities for one representative experiment  expressed as % of the uninduced control that 
was assigned a value of 100 %. (C) AGS cells were incubated with 0, 5, 10, or 25 μM AG82 
in DMSO for 30 min at 37°C. Subsequently all samples were EBV infected by spinoculation 
in presence of AG82. Infection was analyzed after 48 h by flow cytometry measurement of 
GFP expression. Bars represent mean ± SD of three independent experiments. 
 
Fig. 3. PI3K and c-Src signalling augment EBV infection. AGS cells were incubated 
for 1 h at 37°C with either 50 μg/ml Ly294002, 1μM Wortmannin, or 20μM PP2 and 
subsequently spinoculated with EBV as in Fig. 1 but in presence of the inhibitor. Infection 
was analyzed after 48 h by flow cytometry measurement of GFP expression. Bars represent 
mean ± SD of three independent experiments and are expressed as % of a mock-treated 
control that was assigned a value of 100%. 
 
Fig. 4. EBV binding induces remodelling of the actin cytoskeleton facilitating 
infection. (A) AGS cells grown on coverslips were serum starved for 24 h and subsequently 
left uninduced or treated with either 40 μg/ml Fibronectin for 1h or with EBV for 15 min and 
60 min. The cells were fixed in paraformaldehyde, permeabilized and stained with Phalloidin 
coupled to FITC to visualize actin filaments. Samples were mounted in anti-fade reagent 
containing DAPI and analyzed by epifluorescence. (B) AGS cells on coverslips were serum 
starved for 24 h and subsequently treated for 1 h with either 10μM AG82, 50 μg/ml 
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Ly294002, or 20μM PP2. The cells were then either left uninduced (control) or treated with 
EBV for 15 min or 60 min in presence of the inhibitors before fixation and Phalloidin-FITC 
staining as described for (A). (C) AGS cells were treated with 100μM Cytochalasin D (CytD) 
for 1h and subsequently spinoculated with EBV in presence of fresh Cytochalasin D. 
Infection was analyzed after 48h by flow cytometry measurement of GFP expression. Bars 
represent mean ± SD of three independent experiments. 
 
Fig. 5. EBV induces RhoA GTPase in AGS cells. (A) Serum-starved AGS cells were 
either left untreated (mock) or induced with EBV for 5, 15, 30, or 60 min. The cells were 
lysed and equal amounts of lysates were used to capture the GTP-bound form of RhoA by 
affinity precipitation with rhothekin coupled sepharose beads. For positive and negative 
controls the lysates were loaded with GTPγS and GDP respectively prior to precipitation. The 
proteins captured by beads were analyzed by 10% SDS PAGE. Gels were blotted, probed 
with mouse anti-RhoA antibody and visualized by an enhanced chemiluminescence reaction. 
The bottom panel shows normalized cell lysates for total RhoA as a loading control. (B) 
Quantitation of EBV-induced RhoA. The bands from panel A were scanned and their 
intensities quantified after normalization to total RhoA expression. RhoA-GTP levels in mock 
treated cells were considered one-fold activation for comparison to EBV induced cells. Bars 
represent band intensities from one representative experiment. 
 
Fig. 6. EBV induces changes in the microtubule organisation of AGS cells. (A) AGS 
cells grown on coverslips were serum starved for 24 h, left untreated or spinoculated with 
EBV and incubated for 15 min or 60 min at 37°C. The cells were paraformaldehyde fixed, 
permeabilized and stained with anti-α-tubulin (left panels) or anti-acetylated-tubulin mouse 
antibodies and Alexa488 coupled secondary anti-mouse reagent. Samples mounted in anti-
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fade containing DAPI were analyzed by epifluorescence. (B) Serum-starved AGS cells were 
either left untreated (mock) or induced with EBV for 5, 15, 30, or 60 min. The cells were 
lysed in RIPA buffer and lysates cleared of cell debris and nuclei. Supernatants were 
separated by 10% SDS PAGE, Western blotted and probed with anti-acetylated-tubulin and 
anti-α-tubulin as a loading control. Immunoreactive bands were visualized by enhanced-
chemiluminescence. (C) Quantitation of tubulin acetylation. The intensities of bands from the 
upper panel of B were measured and normalized according to total tubulin expression (B 
lower panel). Tubulin acetylation in EBV treated samples was expressed as fold of mock 
treated cells. Bars represent values from one representative experiment.  
 
Fig. 7. FAK-PI3K-Src-RhoA-cytoskeleton signalling pathways in epithelial cells 
induced by EBV. A schematic representation of the EBV-integrin induced hypothetic signal 
cascade deciphered in this study is shown. Following EBV interactions with integrins through 
BMRF-2 binding FAK is activated by auto-phosphorylation at Y397, which will create a 
binding site for SH2 domains of downstream kinases. The downstream kinases involved 
include PI3K and c-Src, even though their order has not been determined yet. Activated 
kinases induce activation of RhoA and its transition in a GTP-bound state, which leads to the 
formation of stress fibres. An as yet unidentified branch of the cascade triggers changes in the 
microtubuli network. Inhibitors of integrins, FAK, PI3K and c-Src used in this study are 
indicated in grey and their point of interference is given with T-bars. Solid arrows depict 
identified pathways, while dashed arrows depict pathways, of which the order has not been 
dissected in this work. Kinases are boxed in grey. 
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Abstract  
Toll-like receptors (TLRs) are key receptors of the innate immune response and show cell-
subset specific expression. We hypothesized that expression and function of TLRs are tailored 
to distinct B-cell development stages. We investigated the mRNA expression of TLR genes in 
hematopoietic stem cells (HSC), in primary B-cells and plasma cells as well as in a panel of 
B-cell lymphomas arisen from distinct B-cells and B-cell precursors. HSC and plasma cells 
were unique by their unrestricted expression of TLR1-TLR9, but almost absence of TLR10. By 
contrast, mature, i.e. naïve and memory B-cells lacked TLR3, TLR4 and TLR8 but expressed 
mRNA of all other TLRs. This expression pattern was largely retained in mature B-cell-
derived malignancies. Immature B-cell-derived malignancies had no TLR3 and TLR4 
suggesting that their expression was lost early after HSC commitment to the B-cell lineage. In 
contrast, TLR8 is lost during transition from immature to mature B-cell. Very importantly, we 
demonstrate effective functioning of TLRs on plasma cells shown by augmented IgM, IgG, or 
total Ig production upon TLR ligand stimulation. The property of TLRs to boost Ig production 
in plasma cells upon pathogen recognition points to a novel role of TLRs which may have 
therapeutic application such as boosting an antibody response. 
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Introduction  
Toll-like receptors (TLRs) are key recognition structures of the innate immunity (1). They 
trigger antimicrobial responses subsequent to their ligation by conserved pathogen-associated 
molecular patterns. The signaling cascade culminates, among others, in the activation of NF-
κB which results in transcription of pro-inflammatory genes critical for the innate as well as 
the adaptive immune responses against pathogens (1). Besides their importance in triggering 
antimicrobial responses, TLRs play a role in autophagy (2), hematopoiesis (3) and neutrophil 
activation (4). For each of the ten known human TLRs (TLR1-TLR10) at least one distinct 
ligand derived from microbial pathogens has been identified except for TLR10. 
Cell subpopulations exhibit specific TLR expression patterns (5, 6) indicating that TLR 
expression is tailored to distinct cellular tasks and functions. Furthermore, TLR expression 
pattern depends on the developmental stage as exemplified by the developmental-dependent 
degree of TLR1-TLR5 expression in dendritic cells (7) and TLR9 in B-cells (8). Delineation of 
TLR expression during human B-cell development is so far incomplete (9). An analysis of all 
known TLRs of human B-cells at their different maturation stages with particular emphasis on 
plasma cells will give a comprehensive image of the TLR profile which is the basis for 
functional studies. 
In the current study, we hypothesized that expression and function of TLRs are tailored to 
distinct stages of B-cell development. Therefore, we investigated expression of TLR1-TLR10 
at distinct B-cell developmental stages including hematopoietic stem cells (HSC),3 naïve and 
memory B-cells as well as plasma cells. The impact of plasma cell TLR triggering on Ig 
production has not been investigated. Thus, we addressed also this functional issue. 
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Materials and Methods 
Cells and subpopulations 
Cells were isolated from cord blood, peripheral blood or tonsils as described (10-12). The 
study was approved by the local ethics committee and written informed consent was obtained 
for all tissue obtained. Cord blood HSC, B-cells and plasma cells were isolated using CD34 
microbeads, the B-cell isolation kit II and CD138 microbeads, respectively according to the 
instructions of the manufacturer (Miltenyi Biotech, Bergisch Gladbach, Germany). Further 
separation of B-cells into naive and memory B cells was performed using the naive-B-cell 
isolation kit (Miltenyi Biotech) or CD27 microbeads (Miltenyi Biotech) (12) . Isolated cell 
populations used for experiments were always >95% pure as determined by flow cytometry. 
Leukemia cell RNA was obtained from the repository of the Division of Oncology, Children’s 
Hospital of Zurich (13). Frozen lymphoma tissue was generously provided from the Institute 
of Surgical Pathology of Zurich (approved by the local ethics committee). The leukemias and 
lymphomas were characterized according to the WHO classification 2001 (14).  
  
Quantitative real-time PCR 
Quantitative real-time PCR was performed for TLR9 and the housekeeping gene 
hydroxymethylbilane-synthase (HMBS) as described (10, 12). TLR10 was analyzed using 
primer/probe on demand (Hs01935337_s1, Assay-on-demand gene expression product, 
Applied Biosystems, Foster City, CA). SYBR Green primers for HMBS and TLR1-TLR8 were 
described earlier (15).  
 
Flow cytometry 
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Flow cytometry using fluorochrome-conjugated monoclonal antibodies to human CD34, 
CD19, CD27, CD138, IgM or IgG (BD Biosciences, Basel, Switzerland) was executed on a 
Cytomics FC500 instrument (Beckman Coulter, Nyon, Switzerland); data were analyzed with 
FlowJo software (Treestar, Ashland, OR).  
 
Intracellular Ig staining and ELISA 
Tonsillar plasma cells were either left untreated or stimulated with 10 μg/mL peptidoglycan 
(TLR1/2 ligand; Fluka, Buchs, Switzerland),  1 μg/mL poly(I:C) (TLR3 ligand; InvivoGen, 
San Diego, California), 10 ng/mL LPS (TLR4 ligand; Sigma-Aldrich, Buchs, Switzerland), 10 
ng/mL Flagellin (TLR5 ligand), 3 μM R-848 (TLR7/8 ligand; InvivoGen), or 2 μM CpG 
ODN 2006 (TLR9 ligand; Eurogentec, Köln, Germany) respectively. 72 hours after 
stimulation, cells were harvested, fixed, permeabilized and stained. Intracellular staining of 
IgM and IgG on plasma cells was performed using fluorchrom-conjugated monoclonal 
antibodies and the BD Cytofix/Cytoperm kit (both from BD Biosciences) according to the 
manufacturer’s instructions.  
The total amount of secreted Ig was determined by an in-house ELISA: briefly, 96-well 
microtiter plates were coated with 10 μg/mL Protein G (Calbiochem, Dietlikon, Switzerland) 
and kept overnight at room temperature in a humid chamber. The Protein G was diluted in a 
carbonate–bicarbonate buffer, pH 9.6. The plates were washed four times with PBS and 
incubated with 200 μL 3% BSA in PBS per well for 1 h at room temperature. After discarding 
the blocking buffer, 50 μL supernatant of the plasma cell samples or serial dilutions of human 
Ig (NIBSC, Hertfordshire, UK) as reference were added to each well and allowed to react for 
30 min at 37 °C. After three washing steps, peroxidase-labeled sheep anti-human Ig 
(Millipore, Munich, Germany) was incubated for 30 min at 37 °C. After three washing steps, 
100 μL of 3,3′,5,5′-tetramethyl-benzidine substrate (Mabtech, Hamburg, Germany) were 
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added and incubated for 30 min at 37 °C in the dark. Reactions were stopped by the addition 
of 50 μL 1 M citrate. The optical density was determined photometrically at 450 nm with 
620 nm as reference filter.  
Results 
Pattern of TLR mRNA expression changes during B-cell development 
The aim of this work was to investigate the expression pattern of TLR1-TLR10 at distinct B 
cell developmental stages. Thus, we analyzed TLR expression in HSC, in naïve and memory 
B cells as well as in plasma cells from the palatine tonsils. In the absence of reliable 
antibodies to quantify TLR at the protein level, we used quantitative real-time PCR. We found 
that HSC and tonsillar plasma cells expressed well all TLRs with the exception of TLR10 (Fig. 
1). In contrast to HSC and plasma cells, we found a complete absence of TLR3, TLR4 and 
TLR8 expression in naïve and memory B-cells while the other TLRs were expressed to a 
variable degree (Fig. 1). Next, we asked whether circulating plasma cells differ in their TLR 
expression from their tonsillar counterparts to exclude that plasma cells exhibit distinct TLR 
expression patterns after exiting secondary lymphoid organs. We found that plasma cells from 
the peripheral blood exhibited the same expression pattern as tonsillar plasma cells (Fig. 2).  
 
Lymphoid malignancies derived from peripheral B-cells largely retain TLR expression 
patterns from the developmental stage of origin 
B-cells at each developmental stage may give rise to malignant B-cells, and malignant B-cells 
often retain characteristics of the developmental stage from which they derive (16). Thus, we 
were particularly interested whether TLR expression may be one of these characteristics. To 
verify this we analyzed 19 malignancies derived from 4 distinct mature, i.e. peripheral B-cell 
developmental stages which would allow comparison to the results reported above for normal 
primary cells. All these malignancies showed almost a complete absence of TLR3, TLR4 and 
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TLR8 expression while the other TLRs were expressed. The only exception to this pattern was 
follicular lymphoma lacking TLR1. By contrast, plasma cell-derived multiple myeloma 
exhibited no TLR10 but all other TLRs (Fig. 3). Thus, TLR mRNA expression patterns in B-
cell malignancies derived from mature, i.e. peripheral B-cell developmental stages were 
similar to those in normal cellular counterparts. This indicates that developmental stage 
related TLR expression is largely retained during malignant transformation.  
 
Bone marrow-derived lymphoid malignancies exhibit TLR mRNA expression patterns distinct 
from hematopoietic stem cells 
In a next step, we wanted to identify the TLR profile in distinct primary B-cell developmental 
stages from the bone marrow. However, for reasons of good clinical practice as well as for 
technical reasons, it is very difficult to obtain these cell subsets in adequate numbers from 
humans. Since there was a very good accordance of TLR profiles between primary mature B-
cells and B-cell lymphomas derived from mature B-cells, we assumed that TLR expression 
will also be retained during malignant transformation of primary B-cells from the bone 
marrow, i.e. immature B-cells, and thus assessing the TLR profile of those malignancies 
would complement our analysis. 
Of 21 bone marrow-derived B-cell malignancies, none expressed TLR3 or TLR4 mRNA but 
expressed all other TLRs (Fig. 3). TLR5 mRNA was present in very low amounts. The only 
exception was common acute lymphoblastic leukemia which expressed minimal amounts of 
TLR4 and no TLR8 mRNA. Hence, bone marrow-derived B-cell malignancies exhibited TLR 
expression patterns similar to peripheral B-cells and not to HSC. The lack of expression of 
TLR3 and TLR4 in bone marrow-derived B-cell malignancies speaks in favor that loss of 
TLR3 and TLR4 expression occurs very early after HSC commit to B-cell lineage. In contrast, 
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the presence of TLR8 in B-cell precursors and lack of TLR8 in mature cells suggest that its 
loss occurs when immature B-cells develop to mature B-cells. 
 
Engagement of TLRs on plasma cells increases Ig production and secretion 
Based on the TLR profile of plasma cells, we wondered whether triggering TLR affects the 
main function of these cells, i.e. Ig production and secretion. Indeed, purified plasma cells 
resulted in increased production of intracellular IgM (Fig. 4A, C) and IgG (Fig. 4B, D) as well 
as secretion of total Ig (Fig. 4E) in response to ligands binding TLR1/2 and TLR3 or TLR9 
and TLR1/2, TLR3, or TLR5, respectively. This increased Ig production/secretion suggests 
that pattern recognition receptors of plasma cells may be critical in regulating the strength of 
an adaptive antibody-mediated immune response and that pattern recognition receptors have 
additional function beyond of their role in the innate immune response. The omnipresent 
TLR1-TLR9 mRNA expression contrasts the selective strong responses to TLR1/2, TLR3, 
TLR5, or TLR9 speaking in favor of a partial uncoupling of TLR expression from its 
function. Here, we provide the first evidence that engagement of TLRs on plasma cells 
increases immunoglobulin production (Fig. 4). 
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Discussion 
In the present study, we aimed to assess the TLR expression patterns at distinct human B-cell 
developmental stages including HSC, naïve and memory B-cells as well as plasma cells and 
to analyze the impact of plasma cell TLR engagement. Indeed, we demonstrated that TLR 
expression patterns display notable changes during peripheral B-cell development, plasma 
cells exhibit TLR expression distinct from naïve and memory B-cells but similar to HSC, and 
engagement of plasma cell TLRs results in augmented Ig production and secretion by these 
cells. These results suggest that TLR expression is tailored to cellular developmental stage 
function.    
 In agreement with published data (5, 6, 17), we found a complete absence of TLR3, 
TLR4 and TLR8 expression in naïve and memory B-cells while the other TLRs were expressed 
in those cells in various amounts. We complemented the characterization of the TLR profile 
in the B-cell lineage by examining plasma cells: we found that plasma cells express all TLRs 
with the exception of TLR10 which is very weakly expressed. In contrast, naïve and memory 
B-cells show a high expression of TLR10. Strikingly, HSC do also virtually not express 
TLR10. Notably, lack of acceptable specificity of antibodies to TLRs (not shown) precluded 
analysis at the protein level. Triggering TLR resulted in increased production of IgM and IgG 
as well as secretion of soluble Ig by plasma cells which also speaks in favor of the functional 
integrity of TLRs and their immunological significance. This increased Ig 
production/secretion points to a novel role of TLRs: TLRs are known for their role in the 
innate immune responses as well as for linking the innate and adaptive immune responses by 
enhancing cellular activation, upregulation of the MHC class molecules and release of 
cytokines; the fact that TLR agonists directly engage in the generation and strength of 
antibody production uncovers a novel role which may have therapeutic application, e.g., 
boosting an antibody response. Noteworthy, we observed preferential production of IgM 
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following triggering of TLR1/2 and of IgG following triggering of TLR3 or TLR9, 
respectively, as well as a preferential secretion of Ig following triggering of TLR1/2, TLR3, 
or TLR5. This may be either due to preferential recognition and specialized function of TLRs 
in plasma cells in response to distinct conserved motifs or due to the preferential isotype Ig 
responses that the plasma cells we purified had. Previous analyses of TLR function in B-cell 
lineages have shown that naïve and memory B-cells respond to TLR agonists by sustaining or 
increasing their TLR expression or inducing expression of proinflammatory cytokines such as 
IL-8 (5, 6, 17). Thus, the data we report outline a higher complexity of TLR function in B-cell 
immunology.   
Our observation on TLR expression by plasma cells from tonsils or peripheral blood is 
divergent from the one reported for plasma cells from the bone marrow which show largely 
absence of TLR expression (18). It is generally agreed that the bone marrow is the primary 
site of long-lived plasma cells which are responsible for at least some persistent antibodies, 
independent of memory B cells and antigen (19). Thus, given their continuous antibody 
production, long-lived plasma cells in the bone marrow may not need a boosting via TLR 
triggering and therefore TLR expression by bone marrow plasma cells may be dispensable.  
The cell-subset specific TLR expression observed here suggests that HSC and periphery 
plasma cells need the expression of TLR1-TLR9 whereas B-cells from secondary lymphoid 
organs need expression of TLR1, TLR2, TLR5-TLR7, TLR9 and TLR10. We speculate that the 
distinct TLR profile of HSC is critical for their differentiation towards a specific cell subset 
depending upon the encountered pathogen recognition pattern to optimize pathogen-driven 
immune responses. Indeed, recent work in mice (3) and humans (20) has demonstrated that 
TLR signals bias HSC toward myelopoiesis directly by replacing endogenous cytokines 
normally required for the survival, proliferation, and development of hematopoietic 
progenitors. In naïve and memory B-cells TLR triggering seems to be restricted to sustaining 
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or increasing their TLR expression or inducing expression of pro-inflammatory cytokines 
such as IL-8 (5, 6, 17). Finally, as we show, peripheral plasma cell TLR engagement 
augments Ig release. Nevertheless, other so far not identified TLR functions in these cell 
subsets may exist.  
 It is extremely difficult to obtain distinct bone marrow-derived, i.e. immature B-cell 
developmental stages from healthy donors. We have validated that mature (periphery) B-cells 
largely retain TLR expression upon malignant transformation. We found expression of TLR1, 
TLR2, TLR5-7, TLR9, and TLR10 in the vast majority and in the three distinct developmental 
stages of origin in mature (peripheral) B-cell-derived malignancies. This comprehensively 
expands on the reported TLR7 and TLR9 expression by B-cell chronic lymphocytic leukemia 
(21, 22) and TLR9 by non-Hodgkin lymphoma (23). By contrast, plasma cell-derived multiple 
myeloma exhibited no TLR10 but all other TLRs, expanding on the reported expression of 
TLR4, TLR7, and TLR9 in multiple myeloma (24). These observations may justify the 
assumption that malignant B-cells derived from immature (bone marrow) B-cells may have 
retained TLR expression of their origin cells. We took advantage of the possibility to assess 
TLR expression in primary lymphoid tumor cells derived from different bone marrow B-cell 
developmental stages. Virtually none of these malignancies expressed TLR3 or TLR4 mRNA 
but all expressed all other TLRs. Thus, bone marrow-derived B-cell malignancies exhibited 
TLR expression patterns similar to peripheral naïve and memory B-cells except for TLR8 and 
distinct from HSC. This may suggest that loss of TLR3 and TLR4 expression occurs very early 
after HSC commit to B-cell lineage and loss of TLR8 expression during the transition from 
immature to mature B cell. Notably, engagement of TLRs on B-cell tumors has been shown to 
induce diverse responses including apoptosis, growth and survival signals, or increased 
immunogenicity (21-24). Thus, it will be challenging to individually characterize tumors prior 
to application of treatments using TLR triggering. 
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In conclusion, we report that TLR expression differ according to B-cell developmental stage. 
TLR1-TLR9 may promote augmentation of antibody production by plasma cells which may 
have therapeutic application. By contrast, TLR10 for which no ligand has been recognized so 
far and which is virtually not expressed in HSC or plasma cells may functionally be linked to 
specific naïve and memory B-cell actions rather than simple pathogen sensing. Finally, TLR 
expression is largely retained during malignant B-cell transformation, and this may impact on 
tumor behavior, but may also be exploited for new treatment strategies. 
It is tempting to speculate that TLR10 mediates a unique function, e. g. interaction with self 
proteins and thereby homing of naïve and memory B-cells to secondary lymphoid organs. 
This speculation is based on TLR10 being expressed at the cell surface (1) and not by cell 
lineages other than B-cell (5, 6, 9, 17), B-cell differentiation to plasma cell requiring among 
others changes in cell-surface proteins and homing (19), on findings of TLR4 recognizing 
host structures (25) and of TOLL guiding dorsal-ventral cell orientation in Drosophila (26).  
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Figure Legends 
FIGURE 1. mRNA expression levels of TLR1-TLR10 show distinct regulation patterns 
during B-cell development. mRNA expression profiling of TLR1-TLR10 in hematopoietic 
stem cells (HSC) isolated from cord blood and naïve and memory B-cells and terminally 
differentiated plasma cells from tonsils. HSC and plasma cells were isolated by positive 
selection using CD34- and CD138-microbeads, respectively. Naïve B-cells and memory B-
cells were isolated using the naïve B-cell isolation kit and a combination of B-cell isolation 
kit II and CD27 microbeads, respectively. Expression of TLR1-TLR10 and housekeeping gene 
hydroxymethylbilane-synthase (HMBS) mRNA was monitored by quantitative real-time PCR.  
Results shown are means ± SD of three biological replicates of one out of three representative 
experiments. * denotes not detectable.  
 
FIGURE 2. Plasma cells from peripheral blood express mRNA of TLR1-TLR9 but only very 
little of TLR10 similar to plasma cells from palatine tonsils. Plasma cells were isolated from 
peripheral blood or palatine tonsils by positive selection using CD138-microbeads (Miltenyi 
Biotech, Bergisch Gladbach, Germany). Following RNA extraction, DNAse treatment, and 
reverse transcription as reported, expression of TLR and housekeeping gene 
hydroxymethylbilane-synthase (HMBS) mRNA was monitored by quantitative real-time PCR. 
Results shown are means ± SD of three biological replicates of one out of three representative 
experiments.  
 
FIGURE 3. Periphery-derived B-cell malignancies largely retain TLRs mRNA expression 
patterns observed in normal B-cells from similar developmental stages. mRNA expression 
profiling of TLR1-TLR10 in various bone-marrow and periphery B-cell developmental stages-
derived human B-cell malignancies. cALL: common acute lymphoblastic leukemia (n = 11); 
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pre-B ALL (n = 4); pro-B ALL (n = 2); B-ALL (n = 3); B-CLL/SLL u: B-cell chronic 
lymphocytic leukemia / small lymphocytic leukemia unmutated (n = 1); MZL: marginal zone 
lymphoma (n = 6); B-CLL/SLL m: B-cell chronic lymphocytic leukemia / small lymphocytic 
leukemia mutated (n = 1); FL: follicular lymphoma (n = 5); DLBCL (GC): diffuse large B cell 
lymphoma germinal center type (n = 3); BL: Burkitt’s lymphoma (n = 1); DLBCL (AC): 
diffuse large B cell lymphoma activated cell type (n = 2); MM: plasma cell myeloma (n = 1). 
Expression of TLR1-TLR10 and housekeeping gene hydroxymethylbilane-synthase (HMBS) 
mRNA was monitored by quantitative real-time PCR. Results are mean ± SD of 3-11 
independent primary tumor biopsy samples. Dashed vertical lines separate different B cell 
developmental stages. * denotes not detectable. 
 
 
FIGURE 4. Triggering of TLRs on plasma cells induces increased production of Ig. 
Intracellular (A) IgM and (B) IgG expression and mean fluorescence intensity of (C) IgM and 
(D) IgG in, and (E) secretion of Ig by plasma cells isolated from tonsils. Results shown are 
means ± SD of three biological replicates of one out of three representative experiments. * P 
< .001; ** P < .01; *** P < .05, by Kruskall-Wallis and Dunn’s multicomparison test. 
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Figure 1 
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Figure 2 
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 Figure 3 
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Figure 4 
 
 
 167
Manuscripts 
9. Microarray Gene Lists 
9.1. Genes regulated exclusively in naïve B cells upon EBV 
transformation 
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9.2. Genes exclusively regulated in memory B cells upon EBV 
transformation 
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9.3. Genes regulated in both, naïve and memory B cells upon EBV 
transformation
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